

=> fil reg

FILE 'REGISTRY' ENTERED AT 17:53:45 ON 11 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7
DICTIONARY FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **202475-60-3** REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(4'-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline
CN WHI-P 131
FS 3D CONCORD
MF C16 H15 N3 O3
CI COM
SR CA
LC STN Files: ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, DRUGNL, DRUGUPDATES,
EMBASE, PHAR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

27 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
27 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:320073

REFERENCE 2: 136:272618

REFERENCE	3:	135:221035
REFERENCE	4:	135:132432
REFERENCE	5:	135:41029
REFERENCE	6:	135:29154
REFERENCE	7:	134:366897
REFERENCE	8:	134:363426
REFERENCE	9:	134:141589
REFERENCE	10:	133:271682

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:59:48 ON 11 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7
DICTIONARY FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can l8

L8 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN **211555-04-3** REGISTRY
CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN WHI-P 154
FS 3D CONCORD
MF C16 H14 Br N3 O3
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, PHAR, SYNTHLINE,
TOXCENTER, USPAT2, USPATFULL



Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
23 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248178


REFERENCE 2: 138:71823
REFERENCE 3: 138:20416
REFERENCE 4: 135:41029
REFERENCE 5: 134:363426
REFERENCE 6: 133:271682
REFERENCE 7: 133:266866
REFERENCE 8: 133:187943
REFERENCE 9: 133:53698
REFERENCE 10: 132:342816

=> d ide can 19 tot

L9 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-85-4 REGISTRY
CN Carbonic acid, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
(1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, carbonate (1:1) (salt)
(9CI)
MF C16 H15 N3 O3 . C H2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 202475-60-3
CMF C16 H15 N3 O3



Salt p

CM 2

CRN 463-79-6
CMF C H2 O3




1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-84-3 REGISTRY
CN Carbonic acid, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
(1:2) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, carbonate (2:1) (salt)
(9CI)
MF C16 H15 N3 O3 . 1/2 C H2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 463-79-6
CMF C H2 O3



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 134:366897

L9 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-83-2 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, nitrate (salt) (9CI)

(CA INDEX NAME)
MF C16 H15 N3 O3 . x H N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 7697-37-2
CMF H N O3




1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-82-1 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, sulfate (salt) (9CI)
(CA INDEX NAME)
MF C16 H15 N3 O3 . x H2 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 7664-93-9

CMF H2 O4 S



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2003 ACS

RN 340176-81-0 REGISTRY


CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)

MF C16 H15 N3 O3 . x Cl H

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CRN (202475-60-3)



● x HCl


1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-80-9 REGISTRY
CN 1,2,3-Propanetriol, 1-(dihydrogen phosphate), compd. with
4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, compd. with
2,3-dihydroxypropyl dihydrogen phosphate (9CI)
MF C16 H15 N3 O3 . x C3 H9 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 57-03-4
CMF C3 H9 O6 P



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 134:366897

L9 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-79-6 REGISTRY
CN Pentanedioic acid, 2-oxo-, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, 2-oxopentanedioate (salt) (9CI)
MF C16 H15 N3 O3 . x C5 H6 O5

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 328-50-7
CMF C5 H6 O5



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897


L9 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-78-5 REGISTRY
CN L-Ascorbic acid, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, L-ascorbate (salt) (9CI)
FS STEREOSEARCH
MF C16 H15 N3 O3 . x C6 H8 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2003 ACS

RN 340176-77-4 REGISTRY

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, benzoate (salt) (9CI)
(CA INDEX NAME)

MF C16 H15 N3 O3 . x C7 H6 O2


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3

CMF C16 H15 N3 O3



CM 2

CRN 65-85-0
CMF C7 H6 O21 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2003 ACS

RN 340176-76-3 REGISTRY

CN Butanedioic acid, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, butanedioate (salt) (9CI)


MF C16 H15 N3 O3 . x C4 H6 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2003 ACS

RN 340176-75-2 REGISTRY

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C16 H15 N3 O3 . x C4 H6 O6


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 202475-60-3


CMF C16 H15 N3 O3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-74-1 REGISTRY
CN Propanedioic acid, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, propanedioate (salt) (9CI)
MF C16 H15 N3 O3 . x C3 H4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 141-82-2
CMF C3 H4 O4




1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-73-0 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, 2-hydroxy-1,2,3-
propanetricarboxylate (salt) (9CI) (CA INDEX NAME)
MF C16 H15 N3 O3 . x C6 H8 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 77-92-9
CMF C6 H8 O7




1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-72-9 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, acetate (salt) (9CI)
(CA INDEX NAME)
MF C16 H15 N3 O3 . x C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 202475-60-3
CMF C16 H15 N3 O3



CM 2

CRN 64-19-7

CMF C2 H4 O2



1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2003 ACS

RN 340176-70-7 REGISTRY

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, methanesulfonate (salt)
(9CI) (CA INDEX NAME)

MF C16 H15 N3 O3 . x C H4 O3 S


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


CM 1

CRN 202475-60-3

CMF C16 H15 N3 O3




CM 2

CRN 75-75-2
CMF C H4 O3 S1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 134:366897

L9 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 340176-69-4 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, 4-methylbenzenesulfonate
(salt) (9CI) (CA INDEX NAME)
MF C16 H15 N3 O3 . x C7 H8 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 202475-60-3
CMF C16 H15 N3 O3

CM 2

CRN 104-15-4
CMF C7 H8 O3 S

1 REFERENCES IN FILE CA (1957 TO DATE)


1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:366897

L9 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 324035-85-0 REGISTRY
CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-,
monohydrochloride, compd. with methanol (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methanol, compd. with 2-bromo-4-[(6,7-dimethoxy-4-
quinazolinyl)amino]phenol monohydrochloride (1:1) (9CI)
MF C16 H14 Br N3 O3 . C H4 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 211555-04-3
CMF C16 H14 Br N3 O3



CM 2

CRN 67-56-1
CMF C H4 O

H₃C-OH


1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:155488

L9 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 303022-14-2 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, monohydrochloride,
compd. with methanol (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methanol, compd. with 4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
monohydrochloride (1:1) (9CI)
MF C16 H15 N3 O3 . C H4 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 188829-39-2 (202475-60-3)
CMF C16 H15 N3 O3 . Cl H



● HCl

CM 2


CRN 67-56-1
CMF C H4 O

H₃C-OH

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:327883

L9 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 296234-84-9 REGISTRY
CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-,
monohydrochloride (9CI) (CA INDEX NAME)
MF C16 H14 Br N3 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (211555-04-3)




● HCl

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:266866

L9 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2003 ACS
RN 188829-39-2 REGISTRY
CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, monohydrochloride (9CI)
(CA INDEX NAME)
MF C16 H15 N3 O3 . Cl H
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (202475-60-3)



● HCl

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:272618

REFERENCE 2: 134:252355

REFERENCE 3: 133:266866

REFERENCE 4: 126:264049

=> d ide can 120

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 157482-36-5 REGISTRY
CN Kinase (phosphorylating), JAK3 protein (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Jak-3 Janus kinase
CN Jak3 kinase
CN JAK3 protein (tyrosine) kinase
CN JAK3 protein kinase
CN JAK3 tyrosine kinase
CN **Janus kinase 3**
CN L-JAK kinase
CN Leukocyte Janus kinase
CN Protein kinase Jak3
MF Unspecified
CI MAN
SR CA
LC STN Files: ADISNEWS, BIOSIS, CA, CAPLUS, CIN, TOXCENTER, USPAT2,
USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
367 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
368 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:336185

REFERENCE 2: 138:319532

REFERENCE 3: 138:315341

REFERENCE 4: 138:302535

REFERENCE 5: 138:252635

REFERENCE 6: 138:248181

REFERENCE 7: 138:238156

REFERENCE 8: 138:236404

REFERENCE 9: 138:220247

REFERENCE 10: 138:215743

=> d his

(FILE 'HOME' ENTERED AT 16:39:15 ON 11 JUN 2003)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 16:39:56 ON 11 JUN 2003
E UCKUN F/AU

L1 432 S E4-E9
L2 5 S L1 AND (CJUN OR C JUN)
L3 28 S L1 AND (JAK3 OR JAK 3)
L4 17 S L1 AND (JANUS KINASE OR JANUSKINASE) () 3
L5 2 S L2 AND L3,L4

L6 1 S L5 AND P/DT
SEL RN

FILE 'REGISTRY' ENTERED AT 16:41:54 ON 11 JUN 2003

L7 6 S E1-E6
L8 2 S L7 AND 3/NR
SEL RN
L9 20 S E7-E8/CRN

FILE 'HCAOLD' ENTERED AT 16:43:49 ON 11 JUN 2003

L10 0 S L8 OR L9

FILE 'USPATFULL, USPAT2' ENTERED AT 16:43:53 ON 11 JUN 2003

L11 33 S L8 OR L9
E UCKUN F/AU
L12 31 S E4-E8 AND L11
E WAYNE/PA
L13 0 S E21 AND L11
E PARKER/PA,CS
L14 25 S E109,E110 AND L11
L15 33 S L11,L12,L14
L16 1 S L15 AND (PD<=19980630 OR PRD<=19980630 OR AD<-19980630)
L17 32 S L15 NOT L16

FILE 'REGISTRY' ENTERED AT 16:47:37 ON 11 JUN 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 16:48:05 ON 11 JUN 2003

FILE 'REGISTRY' ENTERED AT 16:51:41 ON 11 JUN 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 16:52:31 ON 11 JUN 2003

L18 31 S L17 NOT COMPUTER/TI
L19 15 S L18 AND (CJUN OR C JUN OR JAK 3 OR (JANUSKINASE OR JANUS KINA

FILE 'REGISTRY' ENTERED AT 16:55:51 ON 11 JUN 2003

E JANUS KINASE/CN
L20 1 S E7

FILE 'USPATFULL, USPAT2' ENTERED AT 16:57:52 ON 11 JUN 2003

L21 38 S L20
L22 49 S (JAK3 OR JAK 3) (KINASE OR PROTEIN KINASE OR TYROSINE KINASE
L23 107 S JAK KINASE
L24 152 S L21-L23
L25 14 S L18 AND L24
L26 15 S L19,L25
L27 15 S L26 AND L17
L28 0 S L27 AND (CJUN OR C JUN)
L29 32 S L17,L25-L27

FILE 'REGISTRY' ENTERED AT 16:59:48 ON 11 JUN 2003

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 17:00:41 ON 11 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:00:41 ON 11 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l16 bib abs hitstr

L16 ANSWER 1 OF 1 USPATFULL
AN 1998:7076 USPATFULL
TI Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF

receptor tyrosine kinase

IN Myers, Michael R., Reading, PA, United States
 Spada, Alfred P., Lansdale, PA, United States
 Maguire, Martin P., Mont Clare, PA, United States
 Persons, Paul E., King of Prussia, PA, United States

PA Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

PI US 5710158 19980120 <--

AI US 1994-229886 19940419 (8)

RLI Continuation-in-part of Ser. No. US 1993-166199, filed on 23 Dec 1993, now patented, Pat. No. US 5480883 which is a continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Cebulak, Mary C.

LREP Parker, III, Raymond S., Nicholson, James A., Savitzky, Martin F.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1107

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation using said quinazoline compounds and their use in pharmaceutical compositions is described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202475-60-3

(aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

RN 202475-60-3 USPATFULL

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



=> d 129 bib abs hitrn tot

L29 ANSWER 1 OF 32 USPATFULL

AN 2003:17974 USPATFULL

TI Inhibitors of thrombin induced platelet aggregation

IN Uckun, Fatih M., White Bear Lake, MN, UNITED STATES

PA **Parker Hughes Institute**, St. Paul, MN, UNITED STATES (U.S. corporation)
PI US 2003013728 A1 20030116
AI US 2002-157474 A1 20020528 (10)
RLI Continuation of Ser. No. WO 2000-US42345, filed on 29 Nov 2000, UNKNOWN
PRAI US 1999-168179P 19991130 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering a pharmaceutically effective amount of a compound or composition that inhibits **JAK-3** and/or tyrosine phosphorylation of STAT-3 and inhibits thrombin induced platelet aggregation. The condition of platelet aggregation includes hematopoietic and cerebrovascular diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3**, WHI-P 131 **211555-04-3**, WHI-P 154
(JAK-3 inhibitors and/or inhibitors of STAT-3 phosphorylation for inhibitors of thrombin-induced platelet aggregation)
IT **157482-36-5**, Jak3 kinase
(JAK-3 inhibitors and/or inhibitors of STAT-3 phosphorylation for inhibitors of thrombin-induced platelet aggregation)

L29 ANSWER 2 OF 32 USPATFULL

AN 2002:303999 USPATFULL
TI 4-(4'-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S. corporation)
PI US 6482828 B1 20021119
US 2002183340 A1 20021205
AI US 2002-145639 20020514 (10)
RLI Continuation of Ser. No. WO 2000-US31188, filed on 14 Nov 2000
PRAI US 1999-165499P 19991115 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Henley, III, Raymond
LREP Merchant & Gould P.C.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method of preventing the development or recurrence of colorectal cancer in a mammal comprising administering to the mammal, an effective cancer preventative amount of 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **340176-69-4P 340176-70-7P 340176-72-9P**
340176-73-0P 340176-74-1P 340176-75-2P
340176-76-3P 340176-77-4P 340176-78-5P
340176-79-6P 340176-80-9P 340176-81-0P
340176-82-1P 340176-83-2P 340176-84-3P

340176-85-4P

(prepn. and pharmaceutical use of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline and its salts to prevent the development of colorectal cancer)

IT **202475-60-3P**, 4-(4'-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline
(prepn. and pharmaceutical use of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent the development of colorectal cancer)

L29 ANSWER 3 OF 32 USPATFULL

AN 2002:295196 USPATFULL

TI **JAK-3** inhibitors for treating allergic disorders

IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES

Malaviya, Ravi, Shoreview, MN, UNITED STATES

Sudbeck, Elise A., St. Paul, MN, UNITED STATES

PA **Parker Hughes Institute**, St. Paul, MN, UNITED STATES (U.S. corporation)

PI US 2002165243 A1 20021107

AI US 2002-128683 A1 20020423 (10)

RLI Continuation of Ser. No. US 2001-791040, filed on 22 Feb 2001, PENDING
Continuation of Ser. No. US 2000-627342, filed on 28 Jul 2000, GRANTED,
Pat. No. US 6313130 Continuation of Ser. No. US 1999-443847, filed on 19
Nov 1999, GRANTED, Pat. No. US 6177433 Continuation of Ser. No. US
1999-263420, filed on 5 Mar 1999, GRANTED, Pat. No. US 6080747

DT Utility

FS APPLICATION

LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 2149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors of **JAK3 kinase** for the treatment of
allergy, and others are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131

(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

IT **211555-04-3P**, WHI-P154

(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

IT **157482-36-5**, JAK3 kinase

(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

L29 ANSWER 4 OF 32 USPATFULL

AN 2002:288354 USPATFULL

TI Quinazolines for treating brain tumor

IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES

Narla, Rama Krishna, St. Paul, MN, UNITED STATES

Liu, Xing-Ping, Minneapolis, MN, UNITED STATES

PA **Parker Hughes Institute**, Roseville, MN, UNITED STATES, 2665
(U.S. corporation)

PI US 2002161226 A1 20021031

US 6552027 B2 20030422

AI US 2001-903294 A1 20010711 (9)

RLI Continuation of Ser. No. US 1999-361088, filed on 26 Jul 1999, UNKNOWN

DT Utility

FS APPLICATION

LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 1714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel substituted quinoxaline compounds and conjugates useful to inhibit the growth of brain tumor cells and to inhibit adhesion and migration of brain tumor cells. The compounds of the invention include 4-(3'-bromo-4'-hydroxy phenyl)-amino-6,7-dimethoxyquinazoline and this compound covalently bound to EGF.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **211555-04-3DP**, WHI-P154, EGF conjugates
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

IT **202475-60-3P**, WHI-P131 **211555-04-3P**, WHI-P154
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

IT **202475-60-3D**, WHI-P131, EGF conjugates
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

L29 ANSWER 5 OF 32 USPATFULL

AN 2002:251804 USPATFULL

TI Quinoxalines and therapeutic use thereof

IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES

Liu, Xing-Ping, Minneapolis, MN, UNITED STATES

Narla, Rama Krishna, St. Paul, MN, UNITED STATES

PA **Parker Hughes Institute**, Roseville, MN, UNITED STATES (U.S. corporation)

PI US 2002137757 A1 20020926

AI US 2001-923903 A1 20010807 (9)

RLI Continuation of Ser. No. US 2001-779809, filed on 8 Feb 2001, PENDING
Continuation of Ser. No. US 1999-357404, filed on 20 Jul 1999, GRANTED,
Pat. No. US 6258820

PRAI US 1999-125338P 19990319 (60)

US 1999-125145P 19990319 (60)

US 1999-125177P 19990319 (60)

DT Utility

FS APPLICATION

LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 11 Drawing Page(s)

LN.CNT 1903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Quinoxaline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **188829-39-2P 202475-60-3P 211555-04-3P**
296234-84-9P
(prepn. of quinoxalines as antitumor agents)

L29 ANSWER 6 OF 32 USPATFULL

AN 2002:206662 USPATFULL

TI Quinoxaline formulations and therapeutic use thereof

IN Yiv, Seang H., Encinitas, CA, UNITED STATES

Li, Mingshu, St. Paul, MN, UNITED STATES

Uckun, Fatih M., White Bear Lake, MN, UNITED STATES

PA **PARKER HUGHES INSTITUTE** (U.S. corporation)

PI US 2002111360 A1 20020815

AI US 2001-960464 A1 20010919 (9)

RLI Continuation of Ser. No. WO 2000-US7066, filed on 17 Mar 2000, UNKNOWN
PRAI US 1999-125147P 19990319 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2297

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions for parenteral administration of poorly soluble quinazoline compounds in the form of microemulsions or micellar solutions are described. The compositions are useful in treating patients suffering from cancer or having allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**
(prepn. of quinazolines for micellar pharmaceuticals for treatment of allergy and cancer)

IT **211555-04-3P**
(prepn. of quinazolines for micellar pharmaceuticals for treatment of allergy and cancer)

L29 ANSWER 7 OF 32 USPATFULL

AN 2002:106305 USPATFULL

TI **JAK-3** inhibitors for treating allergic disorders

IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES

Malaviya, Ravi, Shoreview, MN, UNITED STATES

Sudbeck, Elise A., St. Paul, MN, UNITED STATES

PA **Parker Hughes Institute**, Roseville, MN, UNITED STATES (U.S. corporation)

PI US 2002055514 A1 20020509

US 6452005 B2 20020917

AI US 2001-791040 A1 20010222 (9)

RLI Continuation of Ser. No. US 2000-627342, filed on 28 Jul 2000, PENDING
Continuation of Ser. No. US 1999-443847, filed on 19 Nov 1999, GRANTED,
Pat. No. US 6177433 Continuation of Ser. No. US 1999-263420, filed on 5
Mar 1999, GRANTED, Pat. No. US 6080747

DT Utility

FS APPLICATION

LREP Attention Brian C. Whipps, MERCHANT & GOULD P.C., P.O. Box 2903,
Minneapolis, MN, 55402-0903

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 2173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors of **JAK3 kinase** for the treatment of
allergy inhibit mast cell degranulation and mediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

L29 ANSWER 8 OF 32 USPATFULL
AN 2002:99484 USPATFULL
TI Estrogens for treating ALS
IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES
Trieu, Vuoung N., Roseville, MN, UNITED STATES
Liu, Xing-Ping, Minneapolis, MN, UNITED STATES
PA **Parker Hughes Institute**, St. Paul, MN (U.S. corporation)
PI US 2002052385 A1 20020502
AI US 2001-7967 A1 20011102 (10)
RLI Continuation of Ser. No. US 1999-455846, filed on 7 Dec 1999, PATENTED
DT Utility
FS APPLICATION
LREP Attention of Kevin C. Harrison, MERCHANT & GOULD P.C., P.O. Box 2903,
Minneapolis, MN, 55402-0903
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for preventing and treating ALS by administering a
phytoestrogen, preferably genistein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **202475-60-3**, 4-(4'-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline
(phytoestrogens for treating amyotrophic lateral sclerosis)

L29 ANSWER 9 OF 32 USPATFULL
AN 2002:78855 USPATFULL
TI Therapeutic compounds
IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES
Sudbeck, Elise A., St. Paul, MN, UNITED STATES
Cetkovic, Marina, Maplewood, MN, UNITED STATES
Malaviya, Ravi, Shoreview, MN, UNITED STATES
Liu, Xing-Ping, Minneapolis, MN, UNITED STATES
PA **Parker Hughes Institute**, St. Paul, MN (U.S. corporation)
PI US 2002042513 A1 20020411
US 6469013 B2 20021022
AI US 2001-858824 A1 20010516 (9)
RLI Division of Ser. No. US 2000-688756, filed on 16 Oct 2000, PENDING
Division of Ser. No. US 1999-378093, filed on 20 Aug 1999, GRANTED, Pat.
No. US 6313129
PRAI US 1998-97365P 19980821 (60)
US 1998-97359P 19980821 (60)
DT Utility
FS APPLICATION
LREP Denise M Kettelberger Ph D, P O BOX 2903, Minneapolis, MN, 55402-0903
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 55 Drawing Page(s)
LN.CNT 2453
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel **JAK-3** inhibitors that
are useful for treating leukemia and lymphoma. The compounds are also
useful to treat or prevent skin cancer, as well as sunburn and
UVB-induced skin inflammation. In addition, the compounds of the present
invention prevent the immunosuppressive effects of UVB radiation, and
are useful to treat or prevent autoimmune diseases, inflammation, and
transplant rejection. The invention also provides pharmaceutical
compositions comprising compounds of the invention, as well as
therapeutic methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 211555-04-3P, WHI-P154
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT 202475-60-3P, WHI-P131
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT 157482-36-5, Jak3 kinase
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)

L29 ANSWER 10 OF 32 USPATFULL
AN 2002:911 USPATFULL
TI Estrogens for treating ALS
IN Uckun, Faith M., White Bear Lake, MN, United States
Trieu, Vuong N., Roseville, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Parker Hughes Institute, St. Paul, MN, United States (U.S.
corporation)
PI US 6334998 B1 20020101
AI US 1999-455846 19991207 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, Dameron L.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for preventing and treating ALS by administering a
phytoestrogen, preferably genistein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 202475-60-3, 4-(4'-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline
(phytoestrogens for treating amyotrophic lateral sclerosis)

L29 ANSWER 11 OF 32 USPATFULL
AN 2001:229676 USPATFULL
TI Lipid lowering quinazoline dietary supplement composition
IN Uckun, Fatih M., White Bear Lake, MN, United States
Trieu, Vuong N., Roseville, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Hughes Institute, St. Paul, MN, United States (U.S. corporation)
PI US 2001051629 A1 20011213
US 6410545 B2 20020625
AI US 2001-892047 A1 20010626 (9)
RLI Continuation of Ser. No. US 2001-754483, filed on 4 Jan 2001, PENDING
Continuation of Ser. No. US 1998-126940, filed on 30 Jul 1998, GRANTED,
Pat. No. US 6172071
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel carbonyl-substituted quinazoline, preferably
4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for
lowering blood cholesterol, including reducing total cholesterol and
LDL-cholesterol levels by administration of the carbonyl quinazolines
and compositions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 202475-60-3P 211555-04-3P
(prepn. of lipid-lowering quinazoline derivs.)

L29 ANSWER 12 OF 32 USPATFULL
AN 2001:221051 USPATFULL
TI **JAK-3** inhibitors for treating allergic disorders
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malavia, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S.
corporation)
PI US 6326373 B1 20011204
AI US 2000-688755 20001016 (9)
RLI Continuation of Ser. No. US 2000-627342, filed on 28 Jul 2000
Continuation of Ser. No. US 1999-443847, filed on 19 Nov 1999, now
patented, Pat. No. US 6177433 Continuation of Ser. No. US 1999-263420,
filed on 5 Mar 1999, now patented, Pat. No. US 6080747
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Merchant & Gould, PC
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 54 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inhibitors of **JAK3 kinase** for the treatment of
allergy inhibit mast cell degranulation and mediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

L29 ANSWER 13 OF 32 USPATFULL
AN 2001:212446 USPATFULL
TI Dimethoxy quinazolines for treating diabetes
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
Cetkovic, Marina, Maplewood, MN, United States
Malaviya, Ravi, Shoreview, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S.
corporation)
PI US 2001044442 A1 20011122
US 6495556 B2 20021217
AI US 2001-812098 A1 20010319 (9)
RLI Continuation of Ser. No. US 1999-378093, filed on 20 Aug 1999, PENDING
PRAI US 1998-97365P 19980821 (60)
US 1998-97359P 19980821 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 55 Drawing Page(s)

LN.CNT 2449

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel **JAK-3** inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **211555-04-3P**, WHI-P154
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **202475-60-3P**, WHI-P131
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **157482-36-5**, Jak3 kinase
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)

L29 ANSWER 14 OF 32 USPATFULL

AN 2001:202636 USPATFULL
TI 6,7-Dimethoxy-4-anilinoquinazolines
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Narla, Rama Krishna, St. Paul, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S. corporation)
PI US 6316454 B1 20011113
AI US 1999-361088 19990726 (9)
RLI Continuation of Ser. No. US 1998-87479, filed on 28 May 1998
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: McKenzie, Thomas
LREP Merchant & Gould, P.C.
CLMN Number of Claims: 15
ECL Exemplary Claim: 6
DRWN 23 Drawing Figure(s); 16 Drawing Page(s)

LN.CNT 1668

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 6,7-Dimethoxy-4-anilinoquinazolines of the formula: ##STR1##

or pharmaceutically acceptable acid addition salts thereof are disclosed. These novel compounds are useful for inducing apoptosis and preventing metastases of brain tumor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **211555-04-3DP**, WHI-P154, EGF conjugates
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
IT **202475-60-3P**, WHI-P131 **211555-04-3P**, WHI-P154
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
IT **202475-60-3D**, WHI-P131, EGF conjugates
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

L29 ANSWER 15 OF 32 USPATFULL

AN 2001:197027 USPATFULL
TI **JAK-3** inhibitors for treating allergic disorders
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malaviya, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States

PA **Parker Hughes Institute**, Roseville, MN, United States (U.S. corporation)
PI US 6313130 B1 20011106
AI US 2000-627342 20000728 (9)
RLI Continuation of Ser. No. US 1999-443847, filed on 19 Nov 1999, now patented, Pat. No. US 6177433 Continuation of Ser. No. US 1999-263420, filed on 5 Mar 1999, now patented, Pat. No. US 6080747
DT Utility
FS GRANTED
EXNAM Primary Examiner: Reamer, James H.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 54 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inhibitors of **JAK3 kinase** for the treatment of allergy inhibit mast cell degranulation and mediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)
IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)
IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)

L29 ANSWER 16 OF 32 USPATFULL
AN 2001:197026 USPATFULL
TI Therapeutic compounds
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
Cetkovic, Marina, Maplewood, MN, United States
Malaviya, Ravi, Shoreview, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Hughes Institute, St. Paul, MN, United States (U.S. corporation)
PI US 6313129 B1 20011106
AI US 1999-378093 19990820 (9)
PRAI US 1998-97365P 19980821 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ford, John M.; Assistant Examiner: Liu, Hong
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 42 Drawing Figure(s); 55 Drawing Page(s)
LN.CNT 2707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel **JAK-3** inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 211555-04-3P, WHI-P154
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT 202475-60-3P, WHI-P131
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT 157482-36-5, Jak3 kinase
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)

L29 ANSWER 17 OF 32 USPATFULL

AN 2001:139546 USPATFULL
TI Quinazolines and therapeutic use thereof
IN Uckun, Fatih M., White Bear Lake, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
Narla, Rama Krishna, St. Paul, MN, United States
PA Hughes Institute, Roseville, MN, United States, 55113 (U.S. corporation)
PI US 2001016588 A1 20010823
US 6358962 B2 20020319
AI US 2001-779809 A1 20010208 (9)
RLI Continuation of Ser. No. US 1999-357404, filed on 20 Jul 1999, PENDING
PRAI US 1999-125338P 19990319 (60)
US 1999-125145P 19990319 (60)
US 1999-125177P 19990319 (60)
DT Utility
FS APPLICATION
LREP Attention: Brian C. Whipps, MERCHANT & GOULD P.C., P.O. Box 2903,
Minneapolis, MN, 55402-0903
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 1920

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Quinazoline compounds and methods for the treatment of cancer and for
the treatment of allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 188829-39-2P 202475-60-3P 211555-04-3P
296234-84-9P
(prepn. of quinazolines as antitumor agents)

L29 ANSWER 18 OF 32 USPATFULL

AN 2001:114629 USPATFULL
TI Lipid-lowering quinazoline derivative
IN Uckun, Fatih M., White Bear Lake, MN, United States
Trieu, Vuong N., Roseville, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Hughes Institute, St. Paul, MN, United States, 55113 (U.S. corporation)
PI US 2001008894 A1 20010719
US 6355645 B2 20020312
AI US 2001-756483 A1 20010312 (9)
RLI Continuation of Ser. No. US 1998-126940, filed on 30 Jul 1998, GRANTED,
Pat. No. US 6172071
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD, P O BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 739

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel carbonyl-substituted quinazoline, preferably
4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for
lowering blood cholesterol, including reducing total cholesterol and
LDL-cholesterol levels by administration of the carbonyl quinazolines

and compositions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202475-60-3P 211555-04-3P

(prepn. of lipid-lowering quinazoline derivs.)

L29 ANSWER 19 OF 32 USPATFULL

AN 2001:107902 USPATFULL

TI Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

IN Uckun, Faith M., White Bear Lake, MN, United States

Liu, Xing-Ping, Minneapolis, MN, United States

Narla, Rama Krishna, St. Paul, MN, United States

PA Parker Hughes Institute, Roseville, MN, United States (U.S. corporation)

PI US 6258820 B1 20010710

AI US 1999-357404 19990720 (9)

PRAI US 1999-125338P 19990319 (60)

US 1999-125145P 19990319 (60)

US 1999-125177P 19990319 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: McKenzie, Thomas

LREP Merchant & Gould P.C.

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN 42 Drawing Figure(s); 18 Drawing Page(s)

LN.CNT 2044

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1##

wherein:

R.sup.a is iodo, (C.sub.1 -C.sub.4)hydroxyalkyl, benzyloxy, OCF.sub.3, SCF.sub.3, SO.sub.3 H, SO.sub.2 F, SO.sub.2 NR.sup.2 R.sup.3 where R.sup.2 is hydrogen or (C.sub.1 -C.sub.4)alkyl and R.sup.3 is hydrogen, (C.sub.1 -C.sub.4)alkyl, or phenyl, NR.sup.2 R.sup.4 where R.sup.2 is hydrogen or (C.sub.1 -C.sub.4)alkyl and R.sup.4 is phenyl; or a group of the formula ##STR2##

wherein R.sup.5 and R.sup.6 are each independently, hydrogen, (C.sub.1 -C.sub.4)alkyl, or (C.sub.1 -C.sub.4)perfluoroalkyl, and R.sup.7 is hydrogen, halo, hydroxy, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)hydroxyalkyl, or N(R.sup.2).sub.2, where R.sup.2 is hydrogen or (C.sub.1 -C.sub.4)alkyl;

n is an integer of 1-4;

R.sup.b is each, independently, hydrogen, halo, hydroxy, mercapto, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)thioalkyl, (C.sub.1 -C.sub.4)hydroxyalkyl, nitro, cyano, methylenedioxy, ethylenedioxy, COCH.sub.3, CF.sub.3, OCF.sub.3, SCF.sub.3, COOH, SO.sub.3 H, SO.sub.2 F, phenyl, or phenyl substituted by a group selected from halo, hydroxy, mercapto, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)thioalkyl, (C.sub.1 -C.sub.4)hydroxyalkyl, amino, nitro, cyano, CF.sub.3, COOH, SO.sub.3 H, SO.sub.2 NR.sup.2 R.sup.3, SO.sub.2 F where R.sup.2 is H or (C.sub.1 -C.sub.4)alkyl and R.sup.3 is H, (C.sub.1 -C.sub.4)alkyl, phenyl, or phenyl substituted by a group as defined above; benzyloxy or benzyloxy substituted on the phenyl portion by a group defined above; NR.sup.2 R.sup.3 where R.sup.2 is H or (C.sub.1 -C.sub.4)alkyl and R.sup.3 is H, (C.sub.1 -C.sub.4)alkyl, phenyl, or phenyl substituted by a group as defined above; and

R.sup.1 is (C.sub.1 -C.sub.4)alkyl or a pharmaceutically acceptable salt thereof; and methods for the treatment of cancer and for the treatment of allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 188829-39-2P 202475-60-3P 211555-04-3P
296234-84-9P

(prepn. of quinazolines as antitumor agents)

L29 ANSWER 20 OF 32 USPATFULL
AN 2001:105515 USPATFULL
TI Power supply unit and computer
IN Odaohhara, Shigefumi, Yamato-shi, Japan
PI US 2001007134 A1 20010705
AI US 2001-754483 A1 20010104 (9)
PRAI JP 2000-424 20000105
DT Utility
FS APPLICATION
LREP FELSMAN, BRADLEY, VADEN,, GUNTER & DILLON, LLP, Suite 350, Lakewood on
the Park, 7600B North Capital of Texas Highway, Austin, TX, 78731
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 889

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A series power supply circuit and a switching power supply circuit are combined within a single power supply unit. The switching power supply circuit provides an efficiency lower than that of the series power supply circuit under a light load and provides an efficiency higher than that of the series power supply circuit under a heavy load. A standby signal that is asserted under a light load and is deasserted under a heavy load is input to a negative logic enable terminal (-EN) of the series power supply circuit through an inverter0. The standbysignal is directly input to the negative logic enable terminal (-EN) of a PWM controller in the switching power supply circuit.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202475-60-3P 211555-04-3P
(prepn. of lipid-lowering quinazoline derivs.)

L29 ANSWER 21 OF 32 USPATFULL
AN 2001:10895 USPATFULL
TI **JAK-3** inhibitors for treating allergic disorders
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malavia, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S.
corporation)
PI US 6177433 B1 20010123
AI US 1999-443847 19991119 (9)
RLI Continuation of Ser. No. US 1999-263420, filed on 5 Mar 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1,11
DRWN 53 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2356

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors of **JAK3 kinase** for the treatment of
allergy inhibit mast cell degranulation and mediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)

IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)

IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)

L29 ANSWER 22 OF 32 USPATFULL
AN 2001:4745 USPATFULL
TI Lipid-lowering quinazoline derivative
IN **Uckun, Faith M.**, White Bear Lake, MN, United States
Trieu, Vuong N., Roseville, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Hughes Institute, St. Paul, MN, United States (U.S. corporation)
PI US 6172071 B1 20010109
AI US 1998-126940 19980730 (9)
DT Patent
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel carbonyl-substituted quinazoline, preferably 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for lowering blood cholesterol, including reducing total cholesterol and LDL-cholesterol levels by administration of the carbonyl quinazolines and compositions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P 211555-04-3P**
(prepn. of lipid-lowering quinazoline derivs.)

L29 ANSWER 23 OF 32 USPATFULL
AN 2000:80756 USPATFULL
TI Therapeutic use of **JAK-3** inhibitors
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malavia, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S. corporation)
PI US 6080748 20000627
AI US 1999-361491 19990726 (9)
RLI Continuation of Ser. No. US 1999-263420, filed on 5 Mar 1999
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2357

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors of **JAK3 kinase** for the treatment of
allergy inhibit mast cell degranulation an dmediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

L29 ANSWER 24 OF 32 USPATFULL
AN 2000:80755 USPATFULL
TI **JAK-3** inhibitors for treating allergic disorders
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malavia, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
PA Hughes Institute, Roseville, MN, United States (U.S. corporation)
PI US 6080747 20000627
AI US 1999-263420 19990305 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Reamer, James H.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 53 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2348

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Inhibitors of **JAK3 kinase** for the treatment of
allergy inhibit mast cell degranulation an dmediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)
IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating
allergic disorders in relation to inhibition of mast cell degranulation
and pharmacokinetics and toxicity)

L29 ANSWER 25 OF 32 USPAT2
AN 2002:303999 USPAT2
TI 4-(4'-HYDROXYPHENYL) AMINO-6,7-DIMETHOXYQUINAZOLINE TO PREVENT
DEVELOPMENT OF COLORECTAL CANCER
IN **Uckun, Fatih M.**, White Bear Lake, MN, UNITED STATES
PA **Parker Hughes Institute**, St. Paul, MN (U.S. corporation)
PI US 2002183340 A1 20021205
AI US 2002-145639 A1 20020514 (10)
RLI Continuation of Ser. No. WO 2000-US31188, filed on 14 Nov 2000, UNKNOWN
PRAI US 1999-165499P 19991115 (60)
DT Utility

FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method of preventing the development or recurrence of colorectal cancer in a mammal comprising administering to the mammal an effective cancer preventive amount of 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 340176-69-4P 340176-70-7P 340176-72-9P
340176-73-0P 340176-74-1P 340176-75-2P
340176-76-3P 340176-77-4P 340176-78-5P
340176-79-6P 340176-80-9P 340176-81-0P
340176-82-1P 340176-83-2P 340176-84-3P
340176-85-4P
(prepn. and pharmaceutical use of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline and its salts to prevent the development of colorectal cancer)

IT 202475-60-3P, 4-(4'-Hydroxyphenyl)amino-6,7-dimethoxyquinazoline
(prepn. and pharmaceutical use of 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent the development of colorectal cancer)

L29 ANSWER 26 OF 32 USPAT2

AN 2002:288354 USPAT2

TI Quinazolines for treating brain tumor

IN Uckun, Fatih M., White Bear Lake, MN, United States

Narla, Rama Krishna, St. Paul, MN, United States

Liu, Xing-Ping, Minneapolis, MN, United States

PA Parker Hughes Institute, Roseville, MN, United States (U.S. corporation)

PI US 6552027 B2 20030422

AI US 2001-903294 20010711 (9)

RLI Continuation of Ser. No. US 1999-361088, filed on 26 Jul 1999, now patented, Pat. No. US 6316454 Continuation of Ser. No. US 1998-87479, filed on 28 May 1998, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: McKenzie, Thomas

LREP Merchant & Gould P.C.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 16 Drawing Page(s)

LN.CNT 1629

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel substituted quinozoline compounds and conjugates useful to inhibit the growth of brain tumor cells and to inhibit adhesion and migration of brain tumor cells. The compounds of the invention include 4-(3'-bromo-4'-hydroxy phenyl)-amino-6,7-dimethoxyquinazoline and this compound covalently bound to EGF.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 211555-04-3DP, WHI-P154, EGF conjugates
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

IT 202475-60-3P, WHI-P131 211555-04-3P, WHI-P154
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

IT 202475-60-3D, WHI-P131, EGF conjugates

(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

L29 ANSWER 27 OF 32 USPAT2
AN 2002:106305 USPAT2
TI **JAK-3** inhibitors for treating allergic disorders
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Malaviya, Ravi, Shoreview, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S. corporation)
PI US 6452005 B2 20020917
AI US 2001-791040 20010222 (9)
RLI Continuation of Ser. No. US 2000-627342, filed on 28 Jul 2000
Continuation of Ser. No. US 1999-443847, filed on 19 Nov 1999, now patented, Pat. No. US 6177433 Continuation of Ser. No. US 1999-263420, filed on 5 Mar 1999, now patented, Pat. No. US 6080747
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Truong, Tamthom N.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 54 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Inhibitors of **JAK3 kinase** for the treatment of allergy inhibit mast cell degranulation and mediator release.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **202475-60-3P**, WHI-P131
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)
IT **211555-04-3P**, WHI-P154
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)
IT **157482-36-5**, JAK3 kinase
(prepn. of quinazoline derivs. as JAK-3 inhibitors for treating allergic disorders in relation to inhibition of mast cell degranulation and pharmacokinetics and toxicity)

L29 ANSWER 28 OF 32 USPAT2
AN 2002:78855 USPAT2
TI Therapeutic compounds
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Sudbeck, Elise A., St. Paul, MN, United States
Cetkovic, Marina, Maplewood, MN, United States
Malaviya, Ravi, Shoreview, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA **Parker Hughes Institute**, St. Paul, MN, United States (U.S. corporation)
PI US 6469013 B2 20021022
AI US 2001-858824 20010516 (9)
RLI Division of Ser. No. US 2000-688756, filed on 16 Oct 2000 Division of Ser. No. US 1999-378093, filed on 20 Aug 1999, now patented, Pat. No. US 6313129
PRAI US 1998-97365P 19980821 (60)
US 1998-97359P 19980821 (60)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
LREP Merchant & Gould P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 70 Drawing Figure(s); 55 Drawing Page(s)
LN.CNT 2653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel **JAK-3** inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **211555-04-3P**, WHI-P154
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **202475-60-3P**, WHI-P131
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **157482-36-5**, Jak3 kinase
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)

L29 ANSWER 29 OF 32 USPAT2

AN 2001:229676 USPAT2

TI Lipid lowering quinazoline dietary supplement composition

IN **Uckun, Fatih M.**, White Bear Lake, MN, United States

Trieu, Vuong N., Roseville, MN, United States

Liu, Xing-Ping, Minneapolis, MN, United States

PA **Parker Hughes Institute**, St. Paul, MN, United States (U.S. corporation)

PI US 6410545 B2 20020625

AI US 2001-892047 20010626 (9)

RLI Continuation of Ser. No. US 2001-756483, filed on 8 Jan 2001, now patented, Pat. No. US 6355645 Continuation of Ser. No. US 1998-126940, filed on 30 Jul 1998, now patented, Pat. No. US 6172071

DT Utility

FS GRANTED

EXNAM Primary Examiner: Criares, Theodore J.

LREP Merchant & Gould P.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel carbonyl-substituted quinazoline, preferably 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for lowering blood cholesterol, including reducing total cholesterol and LDL-cholesterol levels by administration of the carbonyl quinazolines and compositions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **202475-60-3P 211555-04-3P**
(prepn. of lipid-lowering quinazoline derivs.)

L29 ANSWER 30 OF 32 USPAT2

AN 2001:212446 USPAT2

TI Dimethoxy quinazolines for treating diabetes

IN **Uckun, Fatih M.**, White Bear Lake, MN, United States

Sudbeck, Elise A., St. Paul, MN, United States

Cetkovic, Marina, Maplewood, MN, United States

Malaviya, Ravi, Shoreview, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA **Parker Hughes Institute**, Roseville, MN, United States (U.S.
corporation)
PI US 6495556 B2 20021217
AI US 2001-812098 20010319 (9)
RLI Continuation of Ser. No. US 1999-378093, filed on 20 Aug 1999
PRAI US 1998-97365P 19980821 (60)
US 1998-97359P 19980821 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
LREP Merchant & Gould P.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 70 Drawing Figure(s); 55 Drawing Page(s)
LN.CNT 2611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel **JAK-3** inhibitors that
are useful for treating leukemia and lymphoma. The compounds are also
useful to treat or prevent skin cancer, as well as sunburn and
UVB-induced skin inflammation. In addition, the compounds of the present
invention prevent the immunosuppressive effects of UVB radiation, and
are useful to treat or prevent autoimmune diseases, inflammation, and
transplant rejection. The invention also provides pharmaceutical
compositions comprising compounds of the invention, as well as
therapeutic methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **211555-04-3P**, WHI-P154
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **202475-60-3P**, WHI-P131
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)
IT **157482-36-5**, Jak3 kinase
(therapeutic uses of quinazoline derivs. as JAK-3 kinase inhibitors)

L29 ANSWER 31 OF 32 USPAT2

AN 2001:139546 USPAT2
TI 6,7-Dimethoxyquinazolines and therapeutic use thereof
IN **Uckun, Fatih M.**, White Bear Lake, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
Narla, Rama Krishna, St. Paul, MN, United States
PA **Parker Hughes Institute**, St. Paul, MN, United States (U.S.
corporation)
PI US 6358962 B2 20020319
AI US 2001-779809 20010208 (9)
RLI Continuation of Ser. No. US 1999-357404, filed on 20 Jul 1999, now
patented, Pat. No. US 6258820
PRAI US 1999-125338P 19990319 (60)
US 1999-125145P 19990319 (60)
US 1999-125177P 19990319 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: McKenzie,
Thomas
LREP Merchant & Gould, P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 6
DRWN 42 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 1803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Quinazoline compounds and methods for the treatment of cancer and for
the treatment of allergic reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 188829-39-2P 202475-60-3P 211555-04-3P
296234-84-9P

(prepn. of quinazolines as antitumor agents)

L29 ANSWER 32 OF 32 USPAT2
AN 2001:114629 USPAT2
TI Lipid-lowering quinazoline derivative
IN Uckun, Fatih M., White Bear Lake, MN, United States
Trieu, Vuong N., Roseville, MN, United States
Liu, Xing-Ping, Minneapolis, MN, United States
PA Parker Hughes Institute, St. Paul, MN, United States (U.S.
corporation)
PI US 6355645 B2 20020312
AI US 2001-756483 20010108 (9)
RLI Continuation of Ser. No. US 1998-126940, filed on 30 Jul 1998, now
patented, Pat. No. US 6172071
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Truong, Tamthom
N.
LREP Merchant & Gould, P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 746

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel carbonyl-substituted quinazoline, preferably
4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for
lowering blood cholesterol, including reducing total cholesterol and
LDL-cholesterol levels by administration of the carbonyl quinazolines
and compositions thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202475-60-3P 211555-04-3P

(prepn. of lipid-lowering quinazoline derivs.)

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:04:59 ON 11 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2003 VOL 138 ISS 24

FILE LAST UPDATED: 10 Jun 2003 (20030610/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his 130-

(FILE 'REGISTRY' ENTERED AT 16:59:48 ON 11 JUN 2003)

FILE 'USPATFULL, USPAT2' ENTERED AT 17:00:41 ON 11 JUN 2003

FILE 'HCAPLUS' ENTERED AT 17:01:09 ON 11 JUN 2003


L30 37 S L8 OR L9
 L31 33 S WHI() (P131 OR P154 OR P() (131 OR 154)) OR WHIP131 OR WHIP154
 L32 44 S L30, L31
 L33 8 S L32 AND (PD<=19980630 OR PRD<=19980630 OR AD<=19980630)
 L34 6 S L33 AND L1
 L35 6 S L33 AND (HUGHES OR WAYNE OR PARKER)/PA,CS
 L36 8 S L33-L35
 L37 2 S L36 AND (CJUN OR C JUN)
 L38 2 S L36 AND L24
 L39 1 S L36 AND (JANUSKINASE OR JANUS KINASE OR JAK3)
 L40 8 S L36-L39

FILE 'HCAPLUS' ENTERED AT 17:04:59 ON 11 JUN 2003

=> d all hitstr tot 140

L40 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 2000:15019 HCAPLUS
 DN 132:64268
 TI Preparation of 4-anilinoquinazolines and analogs as **JAK3**
 inhibitors
 IN **Uckun, Fatih M.**
 PA **Hughes** Institute, USA
 SO PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-517
 ICS C07D243-34
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000202	A1	20000106	WO 1999-US14923	19990630 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337999	AA	20000106	CA 1999-2337999	19990630 <--
AU 9948515	A1	20000117	AU 1999-48515	19990630 <--
EP 1091739	A1	20010418	EP 1999-932145	19990630 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1998-91150P	P	19980630 <--		
WO 1999-US14923	W	19990630		
OS MARPAT 132:64268				
GI				



- AB Title compds. [I; R = ZR1; R1 = (un)substituted Ph; R6-R8 = H, halo, alkyl, alkoxy, etc.; R9,R10 = H, halo, alkyl, alkoxy,alkanoyl; R9R10 = OCH2O; Z = CHR11, O, S, NR11; R11 = H, alkyl, alkanoyl] were prepd. Thus, I (R6-R8 = H, R9 = R10 = OMe) (II; R = Cl) was aminated by 4-(HO)C6H4NH2 to give II [R = NHC6H4(OH)-4]. Data for biol. activity of I were given.
- ST anilinoquinazoline prepn **JAK3** inhibitor; **cjun** expression inhibitor anilinoquinazoline prepn
- IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (c-jun, mediated disorders; treatment; prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (oncogene, mediated disorders; treatment; prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- IT Antitumor agents
 (prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- IT **157482-36-5**
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (mediated disorders; treatment; prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- IT **202475-60-3P 211555-04-3P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- IT 123-30-8, 4-Hydroxyaniline 13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline 16750-67-7, 4-Amino-2-bromophenol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Goodman, P; J Biol Chem 1998, V273, P17742 HCAPLUS
 - (2) Leonard, W; WO 9703358 A 1997 HCAPLUS
 - (3) Narla, R; Clinical Cancer Research V4(6), P1405 HCAPLUS
 - (4) St Jude Childrens Res Hospital; WO 9503701 A 1995 HCAPLUS
- IT **157482-36-5**
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (mediated disorders; treatment; prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)
- RN 157482-36-5 HCAPLUS
- CN Kinase (phosphorylating), JAK3 protein (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 202475-60-3P 211555-04-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-anilinoquinazolines and analogs as **JAK3** inhibitors)


RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 211555-04-3 HCAPLUS

CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L40 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:764027 HCAPLUS

DN 132:9009

TI Quinazolines and conjugates thereof for treating brain tumors

IN Uckun, Fatih M.; Narla, Rama K.; Liu, Xing-Ping

PA Wayne Hughes Institute, USA

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D239-94

ICS C07D239-88; C07D239-74; A61K031-505

CC 1-6 (Pharmacology)

Section cross-reference(s): 2, 28, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

PI WO 9961428 A1 19991202 WO 1999-US11767 19990528 <--
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2333392 AA 19991202 CA 1999-2333392 19990528 <--
AU 9943173 A1 19991213 AU 1999-43173 19990528 <--
EP 1082311 A1 20010314 EP 1999-953336 19990528 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2002516823 T2 20020611 JP 2000-550834 19990528 <--
US 6316454 B1 20011113 US 1999-361088 19990726 <--
NO 2000005864 A 20010129 NO 2000-5864 20001120 <--
US 2002161226 A1 20021031 US 2001-903294 20010711
US 6552027 B2 20030422
PRAI US 1998-87479 A 19980529 <--
WO 1999-US11767 W 19990528
US 1999-361088 A1 19990726
OS MARPAT 132:9009
AB Substituted quinazoline compds. and conjugates useful for inhibiting the
growth of brain tumor cells and for inhibiting adhesion and migration of
brain tumor cells are provided. The compds. include 4-(3'-bromo-4'-
hydroxyphenyl)amino-6,7-dimethoxyquinazoline and this compd. covalently
bound to e.g. EGF.
ST quinazoline deriv brain cancer treatment; EGF quinazoline conjugate brain
cancer treatment; adhesion brain cancer cell quinazoline deriv; migration
brain cancer cell quinazoline deriv
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to, conjugates; quinazoline derivs., prepn., conjugates,
and use for treating brain tumors)
IT Structure-activity relationship
(antitumor; quinazoline derivs., prepn., conjugates, and use for
treating brain tumors)
IT Antitumor agents
Antitumor agents
(brain; quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)
IT Antibodies
Cytokines
Growth factors, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(conjugates; quinazoline derivs., prepn., conjugates, and use for
treating brain tumors)
IT Neuroglia
(glioblastoma, cell adhesion; quinazoline derivs., prepn., conjugates,
and use for treating brain tumors)
IT Neuroglia
Neuroglia
(glioblastoma, inhibitors; quinazoline derivs., prepn., conjugates, and
use for treating brain tumors)
IT Antitumor agents
(glioblastoma; quinazoline derivs., prepn., conjugates, and use for
treating brain tumors)
IT Brain, neoplasm
Brain, neoplasm

- (inhibitors; quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Brain, neoplasm
(medulloblastoma, cell adhesion; quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Antitumor agents
(metastasis; quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Actins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(polymn.; quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Apoptosis
Cell adhesion
Cell migration
Drug delivery systems
Drug targeting
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Epidermal growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT Biological transport
(uptake; quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT **211555-04-3DP, WHI-P154**, EGF conjugates
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT 62229-50-9, Epidermal growth factor
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT 21561-09-1P, WHI-P 258 153436-54-5P, WHI-P 79 **202475-60-3P**, **WHI-P131 211555-04-3P, WHI-P154** 211555-05-4P, WHI-P 97 211555-06-5P, WHI-P 111 211555-07-6P, WHI-P 132 211555-08-7P, WHI-P180 211555-09-8P, WHI-P 197 251376-04-2P, WHI-P 292
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT 62229-50-9D, Epidermal growth factor, quinazoline deriv. conjugates **202475-60-3D, WHI-P131**, EGF conjugates 251347-48-5 251347-49-6 251347-50-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)
- IT 62-53-3, Benzenamine, reactions 95-55-6, 2-Hydroxyaniline 123-30-8, 4-Hydroxyaniline 591-19-5, 3-Bromoaniline 591-27-5, 3-Hydroxyaniline 609-21-2, 3,5-Dibromo-4-hydroxyaniline 2834-92-6 3964-52-1, 3-Chloro-4-hydroxyaniline 7745-91-7, 3-Bromo-4-methylaniline 13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline 16750-67-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; quinazoline derivs., prepn., conjugates, and use for
treating brain tumors)


RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Narla, R; Clinical Cancer Research 1998, V4(6), P1405 HCAPLUS
- (2) Rhone-Poulenc; WO 9515758 A 1995 HCAPLUS
- (3) Zeneca; EP 0566226 A 1993 HCAPLUS
- (4) Zeneca; WO 9615118 A 1996 HCAPLUS
- (5) Zeneca; WO 9730035 A 1997 HCAPLUS
- (6) Zeneca; WO 9732856 A 1997 HCAPLUS

IT **211555-04-3DP, WHI-P154**, EGF conjugates
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); PROC (Process); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating brain
tumors)

RN 211555-04-3 HCAPLUS

CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX
NAME)




IT **202475-60-3P, WHI-P131 211555-04-3P,**
WHI-P154


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating brain
tumors)

RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-04-3 HCAPLUS
 CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



IT 202475-60-3D, WHI-P131, EGF conjugates
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)

RN 202475-60-3 HCAPLUS
 CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L40 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 1998:698779 HCAPLUS
 DN 130:104886
 TI Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154)
 AU Narla, Rama Krishna; Liu, Xing-Ping; Klis, Daniel; Uckun, Fatih M.
 CS Drug Discovery Program, Department of Experimental Oncology, Wayne Hughes Institute, St. Paul, MN, 55113, USA
 SO Clinical Cancer Research (1998), 4(10), 2463-2471
 CODEN: CCREF4; ISSN: 1078-0432
 PB American Association for Cancer Research
 DT Journal
 LA English
 CC 1-6 (Pharmacology)

- AB Glioblastoma multiforme is a highly invasive primary brain tumor with a disappointingly high local recurrence rate and mortality despite intensive multimodality treatment programs. Therefore, new agents that are capable of inhibiting the infiltration of normal brain parenchyma by glioblastoma cells are urgently needed. Here, we show that the novel quinazoline derivs. 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P131**) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P154**) are potent inhibitors of glioblastoma cell adhesion and migration. Specifically, both compds. inhibited at micromolar concns.: (a) integrin-mediated glioblastoma cell adhesion to the extracellular matrix proteins laminin, type IV collagen, and fibronectin; (b) integrin-independent epidermal growth factor-induced adhesion of glioblastoma cells to poly-L-lysine-coated tissue culture plates; (c) fetal bovine serum-induced polymn. of actin and actin stress fiber formation as well epidermal growth factor-stimulated formation of focal adhesion plaques in serum-starved glioblastoma cells; and most importantly, (d) glioblastoma cell migration in in vitro assays of tumor cell invasiveness using tumor cell spheroids and/or Matrigel-coated Boyden chambers. Further preclin. development of **WHI-P131** and **WHI-P154** may provide the basis for the design of more effective adjuvant chemotherapy programs for glioblastoma multiforme.
- ST glioblastoma cell adhesion migration dimethoxyquinazoline **WHIP131**
WHIP154
- IT Neuroglia
(glioblastoma multiforme; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Neuroglia
(glioblastoma, inhibitors; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Antitumor agents
(glioblastoma; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Cell adhesion
Cell migration
(inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Actins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of serum-induced actin polymn. and actin stress fiber formation in human glioblastoma cells by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Extracellular matrix
(integrin-mediated glioblastoma cell adhesion to extracellular matrix proteins; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Integrins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(integrin-mediated glioblastoma cell adhesion to extracellular matrix proteins; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)
- IT Fibronectins
Laminins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(integrin-mediated glioblastoma cell adhesion to extracellular matrix proteins; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)

IT Organelle

(stress fiber; inhibition of serum-induced actin polymn. and actin stress fiber formation in human glioblastoma cells by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)

IT Collagens, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(type IV, integrin-mediated glioblastoma cell adhesion to extracellular matrix proteins; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)

IT 62229-50-9, Epidermal growth factor

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(EGF-induced adhesion and formation of focal adhesion plaques; inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)

IT 202475-60-3, **WHI-P 131**

211555-04-3, **WHI-P 154**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines **WHI-P131** and **WHI-P154**)

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Berens, M; Neurosurg Clin N Am 1990, V1, P1 MEDLINE
- (2) Bos, M; Clin Cancer Res 1997, V3, P2099 HCAPLUS
- (3) Brandes, A; Cancer Invest 1996, V14, P551 HCAPLUS
- (4) Bretcher, M; Cell 1996, V87, P601
- (5) Burrridge, K; Annu Rev Cell Biol 1988, V4, P487 HCAPLUS
- (6) Burrridge, K; Bioessays 1989, V10, P104 HCAPLUS
- (7) Burrridge, K; Cell Differ Dev 1990, V32, P337 HCAPLUS
- (8) Carbonetto, S; Trends Neurosci 1984, V7, P382
- (9) Chen, H; J Biol Chem 1995, V270, P16995 HCAPLUS
- (10) Chen, Q; J Biol Chem 1996, V271, P18122 HCAPLUS
- (11) Chintala, S; Clin Exp Metastasis 1996, V14, P358 HCAPLUS
- (12) Chrzanowska-Wodnicka, M; J Cell Biol 1996, V133, P1403 HCAPLUS
- (13) Cobb, B; Mol Cell Biol 1994, V14, P147 HCAPLUS
- (14) Devaux, B; J Neurosurg 1993, V78, P767 MEDLINE
- (15) Finchman, V; EMBO J 1998, V17, P81
- (16) Finlay, J; Pediatric Neuro-Oncology 1992, P278
- (17) Fry, D; Science 1994, V265, P1093 HCAPLUS
- (18) Grossman, S; Semin Oncol 1995, V22, P530 HCAPLUS
- (19) Hatai, M; FEBS Lett 1994, V350, P113 HCAPLUS
- (20) Klemke, R; J Cell Biol 1997, V137, P481 HCAPLUS
- (21) Kreth, F; J Neurosurg 1993, V78, P762 MEDLINE
- (22) Machesky, L; J Cell Biol 1997, V138, P913 HCAPLUS
- (23) Miyamoto, S; J Cell Biol 1996, V135, P1633 HCAPLUS
- (24) Miyamoto, S; Science 1995, V267, P883 HCAPLUS
- (25) Narla, R; Clin Cancer Res 1998, V4, P1405 HCAPLUS
- (26) Nomoto, F; Chem Pharm Bull 1990, V38, P1591
- (27) Ouwers, D; Biochem J 1996, V318, P609 HCAPLUS
- (28) Pardos, M; Cancer Medicine 1997, V1, P1471
- (29) Pardos, M; Semin Surg Oncol 1998, V14, P88

- (30) Petch, L; J Cell Sci 1995, V108, P1371 HCAPLUS
- (31) Price, J; Eur J Cancer 1996, V32, P1977
- (32) Quigley, M; Neurosurgery 1991, V29, P385 MEDLINE
- (33) Rohde-Schulz, B; Invasion Metastasis 1995, V15, P1 HCAPLUS
- (34) Russel, D; Pathology of Tumors of the Nervous System Ed 5 1989, P83
- (35) Rutka, J; J Neurosurg 1988, V69, P155 HCAPLUS
- (36) Sato, M; Cancer Lett 1996, V102, P183 HCAPLUS
- (37) Schaller, M; Curr Opin Cell Biol 1994, V6, P705 HCAPLUS
- (38) Schwarzbauer, J; Curr Biol 1997, V7, P292
- (39) Solic, N; Exp Cell Res 1997, V234, P465 HCAPLUS
- (40) Symons, M; J Cell Biol 1991, V114, P503 HCAPLUS
- (41) Thomas, C; Catalytic Processes and Proven Catalysts 1970
- (42) Venstrom, K; FASEB J 1993, V7, P996 HCAPLUS
- (43) Wang, Y; J Cell Biol 1984, V99, P1478 MEDLINE
- (44) Yoshida, D; Neurosurgery 1996, V39, P360 MEDLINE
- (45) Zachary, I; Int J Biochem Cell Biol 1997, V29, P929 HCAPLUS

IT 202475-60-3, WHI-P 131


211555-04-3, WHI-P 154

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of human glioblastoma cell adhesion and invasion by the dimethoxyquinazolines WHI-P131 and WHI-P154)


RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 211555-04-3 HCAPLUS

CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



- L40 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:529827 HCAPLUS
TI 4-(3'-bromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P154**): A novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells
AU Narla, R. K.; Liu, X.; Myers, D. E.; Venkatachalam, T.; **Uckun, F. M.**
CS Department Experimental Oncology, **Wayne Hughes** Institute, St. Paul, MN, 55113, USA
SO Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-342 Publisher: American Chemical Society, Washington, D. C.
CODEN: 66KYA2
DT Conference; Meeting Abstract
LA English
AB The novel quinazoline **WHI-P154** exhibited significant cytotoxicity against two glioblastoma cell lines causing apoptotic cell death at micromolar concns. In vitro anti-glioblastoma activity of **WHI-P154** was amplified >200-fold and rendered selective by conjugation to EGF. In vitro treatment with EGF-P154 resulted in killing of glioblastoma cells at nanomolar concns. In vivo administration of EGF-P154 resulted in delayed tumor progression and improved tumor-free survival in a SCID mouse glioblastoma xenograft model. Thus, targeting **WHI-P154** to the EGF-R may be useful in the treatment of glioblastoma.
- L40 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:492839 HCAPLUS
DN 129:213579
TI Role of tyrosine kinases in induction of the **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells
AU Goodman, Patricia A.; Niehoff, Lisa B.; **Uckun, Fatih M.**
CS Department of Molecular Genetics, **Wayne Hughes** Institute, St. Paul, MN, 55113, USA
SO Journal of Biological Chemistry (1998), 273(28), 17742-17748
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
CC 8-7 (Radiation Biochemistry)
Section cross-reference(s): 28
AB Exposure of B-lineage lymphoid cells to ionizing radiation induces an elevation of **c-jun** proto-oncogene mRNA levels. This signal is abrogated by protein-tyrosine kinase (PTK) inhibitors, indicating that activation of an as yet unidentified PTK is mandatory for radiation-induced **c-jun** expression. Here, we provide exptl. evidence that the cytoplasmic tyrosine kinases BTK, SYK, and LYN are not required for this signal. Lymphoma B-cells rendered deficient for LYN, SYK, or both by targeted gene disruption showed increased **c-jun** expression levels after radiation exposure, but the magnitude of the stimulation was lower than in wild-type cells. Thus, these PTKs may participate in the generation of an optimal signal. Notably, an inhibitor of JAK-3 (Janus family kinase-3) abrogated radiation-induced **c-jun** activation, prompting the hypothesis that a chicken homolog of JAK-3 may play a key role in initiation of the radiation-induced **c-jun** signal in B-lineage lymphoid cells.
ST gamma irradiation **cjun** lymphocyte tyrosine kinase
IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**c-jun**; role of tyrosine kinases in induction of

c-jun proto-oncogene in irradiated B-lineage lymphoid cells)

- IT Gamma ray
(irradn.; role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)
- IT B cell (lymphocyte)
(role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)
- IT **202475-60-3P 211555-04-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)
- IT 80449-02-1, Tyrosine kinase 138674-26-7, SYK Tyrosine kinase 140208-17-9, LYN Tyrosine kinase 149147-12-6, Bruton's Tyrosine kinase **157482-36-5, JAK-3 kinase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)
- IT 123-30-8 4998-07-6 16750-67-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)
- IT 4959-60-8P 5004-88-6P 13790-39-1P 13794-72-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(role of tyrosine kinases in induction of **c-jun** proto-oncogene in irradiated B-lineage lymphoid cells)

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Angel, P; Nature 1988, V332, P166 HCAPLUS
- (2) Aoki, Y; Proc Natl Acad Sci U S A 1994, V91, P10606 HCAPLUS
- (3) Bohmann, D; Science 1998, V238, P1386
- (4) Chae, H; Cancer Res 1993, V53, P447 HCAPLUS
- (5) Chen, Y; J Biol Chem 1996, V271, P31929 HCAPLUS
- (6) Chomczynski, P; Biochemistry 1987, V162, P156 HCAPLUS
- (7) Collotta, F; J Biol Chem 1992, V267, P18278
- (8) Danial, N; Science 1995, V269, P1875 HCAPLUS
- (9) Demoulin, J; Mol Cell Biol 1996, V16, P4710 HCAPLUS
- (10) Derijard, B; Cell 1994, V76, P1025 HCAPLUS
- (11) Dibirdik, I; J Biol Chem 1998, V273, P4035 HCAPLUS
- (12) Dosch, J; Oncogene 1996, V13, P1927 HCAPLUS
- (13) Feinberg, A; Anal Biochem 1983, V132, P6 HCAPLUS
- (14) Friedman, R; Nature 1985, V314, P637 HCAPLUS
- (15) Fusaki, N; J Biol Chem 1997, V272, P6214 HCAPLUS
- (16) Gurniak, C; Blood 1996, V87, P3151 HCAPLUS
- (17) Ham, J; Neuron 1995, V14, P927 HCAPLUS
- (18) Hanissian, S; Immunity 1997, V6, P379 HCAPLUS
- (19) Haque, S; Proc Natl Acad Sci U S A 1997, V94, P8563 HCAPLUS
- (20) Hibbs, M; Cell 1995, V83, P301 HCAPLUS
- (21) Hibi, M; Genes Dev 1993, V7, P2135 HCAPLUS
- (22) Hoffman, S; Genomics 1997, V43, P109 HCAPLUS
- (23) Ihle, J; Bioessays 1996, V18, P95 HCAPLUS
- (24) Ihle, J; Philos Trans R Soc Lond B Biol Sci 1996, V351, P159 HCAPLUS
- (25) Johnston, J; J Biol Chem 1995, V270, P28527 HCAPLUS
- (26) Jugloff, L; J Immunol 1997, V159, P1096 HCAPLUS
- (27) Kaneko, S; Clin Exp Immunol 1997, V109, P185 HCAPLUS
- (28) Karin, M; Curr Opin Cell Biol 1997, V9, P240 HCAPLUS
- (29) Kharbanda, S; J Clin Invest 1990, V86, P1517 HCAPLUS
- (30) Kumar, A; Oncogene 1996, V13, P2009 HCAPLUS
- (31) Kurosaki, T; Curr Opin Immunol 1997, V9, P309 HCAPLUS
- (32) Kurosaki, T; J Exp Med 1995, V182, P1815 HCAPLUS

- (33) Larner, A; J Biol Chem 1986, V261, P453 HCAPLUS
- (34) Larner, A; Proc Natl Acad Sci U S A 1984, V81, P6733 HCAPLUS
- (35) Law, D; Curr Biol 1993, V3, P645 HCAPLUS
- (36) Leonard, W; Nat Med 1996, V2, P968 HCAPLUS
- (37) Levy, D; Cytokine and Growth Factor Rev 1997, V8, P81 HCAPLUS
- (38) Mitchell, P; Science 1989, V245, P371 HCAPLUS
- (39) Musti, A; Science 1997, V275, P400 HCAPLUS
- (40) Myers, D; Proc Natl Acad Sci U S A 1995, V92, P9575 HCAPLUS
- (41) Naka, T; Nature 1997, V387, P924 HCAPLUS
- (42) Neuberg, M; Nature 1989, V341, P589
- (43) Nomoto, F; Chem Pharm Bull (Tokyo) 1990, V38, P1591
- (44) Nosaka, T; Science 1995, V270, P800 HCAPLUS
- (45) Qin, S; J Biol Chem 1997, V272, P2098 HCAPLUS
- (46) Rathbun, R; Blood V90, P974 HCAPLUS
- (47) Riedy, M; Genomics 1996, V37, P57 HCAPLUS
- (48) Rolling, C; FEBS Lett 1996, V393, P53 HCAPLUS
- (49) Rolling, C; Oncogene 1995, V10, P1757 HCAPLUS
- (50) Rosette, C; Science 1996, V274, P1194 HCAPLUS
- (51) Rubin, E; Mol Pharmacol 1991, V39, P697 HCAPLUS
- (52) Ryder, K; Proc Natl Acad Sci U S A 1998, V85, P1487
- (53) Safford, M; Exp Hematol (N Y) 1997, V25, P374 HCAPLUS
- (54) Safford, M; Exp Hematol (N Y) 1997, V25, P650
- (55) Saouaf, S; Proc Natl Acad Sci U S A 1994, V91, P9524 HCAPLUS
- (56) Schutte, J; Cell 1989, V59, P987 MEDLINE
- (57) Sharfe, N; Clin Exp Immunol 1997, V108, P552 HCAPLUS
- (58) Sharfe, N; J Immunol 1997, V159, P1107 HCAPLUS
- (59) Takata, M; J Exp Med 1995, V182, P907 HCAPLUS
- (60) Thomas, C; Catalytic Processes and Proven Catalysts 1970
- (61) Thomis, D; Science 1995, V270, P794 HCAPLUS
- (62) Tortolani, P; J Immunol 1995, V155, P5220 HCAPLUS
- (63) Tuel-Ahlgren, L; Leuk Lymphoma 1996, V20, P417 MEDLINE
- (64) Uckun, F; J Clin Invest 1993, V91, P1044 HCAPLUS
- (65) Uckun, F; Science 1995, V267, P886 MEDLINE
- (66) Uckun, F; Science 1996, V273, P1096 HCAPLUS
- (67) Verheij, M; Nature 1996, V380, P75 HCAPLUS
- (68) Witthuhn, B; Leuk Lymphoma, in press 1998
- (69) Yin, T; J Biol Chem 1995, V270, P20497 HCAPLUS


IT 202475-60-3P 211555-04-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(role of tyrosine kinases in induction of **c-jun**
proto-oncogene in irradiated B-lineage lymphoid cells)


RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 211555-04-3 HCAPLUS

CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



IT 157482-36-5, JAK-3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of tyrosine kinases in induction of **c-jun**
proto-oncogene in irradiated B-lineage lymphoid cells)

RN 157482-36-5 HCAPLUS

CN Kinase (phosphorylating), JAK3 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L40 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:401227 HCAPLUS

DN 129:170172

TI 4-(3'-Bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells

AU Narla, Rama Krishna; Liu, Xing-Ping; Myers, Dorothea E.; Uckun, Fatih M.

CS Department of Experimental Oncology, Hughes Institute, St. Paul, MN, 55113, USA

SO Clinical Cancer Research (1998), 4(6), 1405-1414
CODEN: CCREF4; ISSN: 1078-0432

PB American Association for Cancer Research

DT Journal

LA English

CC 1-6 (Pharmacology)

AB The novel quinazoline deriv. 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P154**) exhibited significant cytotoxicity against U373 and U87 human glioblastoma cell lines, causing apoptotic cell death at micromolar concns. The in vitro antiglioblastoma activity of **WHI-P154** was amplified >200-fold and rendered selective by conjugation to recombinant human epidermal growth factor (EGF). The EGF-P154 conjugate was able to bind to and enter target glioblastoma cells within 10-30 min via receptor (R)-mediated endocytosis by inducing internalization of the EGF-R mols. In vitro treatment with EGF-P154 resulted in killing of glioblastoma cells at nanomolar concns. with an IC₅₀ of 813 +/- 139 nM, whereas no cytotoxicity against EGF-R-neg. leukemia cells was obsd., even at concns. as high as 100 .mu.M. The in vivo administration of EGF-P154 resulted in delayed tumor progression and improved tumor-free survival in a severe combined immunodeficient mouse glioblastoma xenograft model. Whereas none of the control mice remained alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and all control mice had tumors that rapidly progressed to reach an av. size of >500 mm³ by 58 days, 40% of mice treated for 10 consecutive days with 1 mg/kg/day EGF-P154 remained alive and free of

- detectable tumors for more than 58 days with a median tumor-free survival of 40 days. The tumors developing in the remaining 60% of the mice never reached a size >50 mm³. Thus, targeting **WHI-P154** to the EGF-R may be useful in the treatment of glioblastoma multiforme.
- ST quinazoline deriv **WHIP154** glioblastoma antitumor
- IT Drug targeting
(glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT Epidermal growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT Neuroglia
(glioblastoma, inhibitors; glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT Antitumor agents
(glioblastoma; glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT 62229-50-9D, Epidermal growth factor, conjugates with quinazoline deriv.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT 21561-09-1P 153436-54-5P 202475-60-3P 211555-04-3P 211555-05-4P 211555-06-5P 211555-07-6P 211555-08-7P 211555-09-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)
- IT 13790-39-1P, 4-Chloro-6,7-dimethoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(glioblastoma inhibition by quinazoline deriv. **WHI-P154** targeting of EGF receptor)

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anderson, P; Cancer Res 1995, V55, P1321 HCAPLUS
- (2) Bos, M; Clin Cancer Res 1997, V3, P2099 HCAPLUS
- (3) Brandes, A; Cancer Invest 1996, V14, P551 HCAPLUS
- (4) Covey, T; Rapid Commun Mass Spectrom 1988, V2, P249 HCAPLUS
- (5) Feng, R; J Am Soc Mass Spectrom 1991, V2, P387 HCAPLUS
- (6) Finlay, J; Pediatric Neuro-Oncology 1992, P278
- (7) Friedman, S; Cancer Res 1995, V55, P2853
- (8) Fry, D; Science (Washington DC) 1994, V265, P1093 HCAPLUS
- (9) Hoi, S; J Neurosurg 1995, V82, P841
- (10) Khazaie, K; Cancer Metastasis Rev 1993, V12, P255 HCAPLUS
- (11) Maruno, M; J Neurosurg 1991, V75, P97 MEDLINE
- (12) Mendelsohn, J; Biologic Therapy of Cancer: Principles and Practice 1995, P607
- (13) Nomoto, F; Chem Pharm Bull 1990, V38, P1591
- (14) Pardos, M; Cancer Medicine 1997, VI, P1471
- (15) Pardos, M; Semin Surg Oncol 1998, V14, P88
- (16) Thomas, C; Catalytic Processes and Proven Catalysts 1970, P1
- (17) Torp, S; Cancer Immunol Immunother 1991, V33, P61 HCAPLUS
- (18) Uckun, F; Clin Cancer Res 1998, V4, P1125 HCAPLUS
- (19) Uckun, F; Clin Cancer Res 1998, V4, P901 HCAPLUS
- (20) Uckun, F; J Clin Oncol 1997, V15, P2214 MEDLINE
- (21) Uckun, F; Science (Washington DC) 1995, V267, P886 MEDLINE
- (22) Waurzyniak, B; Clin Cancer Res 1997, V3, P881 HCAPLUS
- (23) Yamazaki, H; Mol Cell Biol 1988, V8, P1816 HCAPLUS

IT 202475-60-3P 211555-04-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(glioblastoma inhibition by quinazoline deriv. **WHI-**

P154 targeting of EGF receptor)


RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 211555-04-3 HCAPLUS

CN Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L40 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:105843 HCAPLUS

DN 128:136497

TI Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

IN Myers, Michael R.; Spada, Alfred P.; Maguire, Martin P.; Persons, Paul E.

PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SO U.S., 19 pp., Cont.-in-part of U.S. 5,480,883.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-505

ICS C07D239-88; C07D239-93; C07D239-94

NCL 514259000

CC 1-3 (Pharmacology)

FAN.CNT 7

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```

-----
PI  US 5710158      A    19980120      US 1994-229886    19940419 <--
    US 5480883      A    19960102      US 1993-166199    19931210 <--
    WO 9515758      A1   19950615      WO 1994-US14180    19941208 <--
      W:  AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB,
          GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW,
          NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
      RW:  KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
          MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
          TD, TG

    AU 9513050      A1   19950627      AU 1995-13050      19941208 <--
    EP 871448      A1   19981021      EP 1995-904308     19941208 <--
      R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE
    US 5656643      A    19970812      US 1995-385258     19950208 <--
    US 5714493      A    19980203      US 1996-652444     19960604 <--
    US 37650        E    20020409      US 2000-496399     20000202 <--
PRAI US 1991-698420 B2   19910510    <--
    US 1992-988515 B2   19921210    <--
    US 1993-166199 A2   19931210    <--
    WO 1992-US3736 A2   19920506    <--
    US 1993-146072 A3   19931108    <--
    US 1994-229886 A    19940419    <--
    WO 1994-US14180 W    19941208    <--
    US 1996-652444 A5   19960604    <--
OS  MARPAT 128:136497
AB  This invention relates to the modulation and/or inhibition of cell
    signaling, cell proliferation, cell inflammatory response, the control of
    abnormal cell growth and cell reprodn. More specifically, this invention
    relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline
    compds. in inhibiting cell proliferation, including compds. which are
    useful protein tyrosine kinase (PTK) inhibitors. The method of treating
    cell proliferation using said quinazoline compds. and their use in
    pharmaceutical compns. is described. A no. of compds. were tested for
    inhibition of PDGF receptor cell-free antophosphorylation procedure.
ST  quinazoline aryl EGF PDGF kinase inhibitor; EGF tyrosine kinase inhibitor
    quinazoline aryl; PDGF tyrosine kinase inhibitor quinazoline aryl;
    heteroaryl quinazoline EGF PDGF kinase inhibitor
IT  Anti-inflammatory agents
    Cell proliferation
      (aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF
      receptor tyrosine kinase)
IT  Epidermal growth factor receptors
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
      (Biological study); PROC (Process)
      (inhibitors; aryl and heteroaryl quinazoline compds. which inhibit EGF
      and/or PDGF receptor tyrosine kinase)
IT  Platelet-derived growth factors
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
      (Biological study); PROC (Process)
      (receptors, inhibitors; aryl and heteroaryl quinazoline compds. which
      inhibit EGF and/or PDGF receptor tyrosine kinase)
IT  Platelet-derived growth factor receptors
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
      (Biological study); PROC (Process)
      (.beta., inhibitors; aryl and heteroaryl quinazoline compds. which
      inhibit EGF and/or PDGF receptor tyrosine kinase)
IT  21561-09-1 21561-11-5 37514-62-8 88404-44-8 146535-68-4
    146885-03-2 153436-53-4 153437-65-1 153437-80-0 167410-34-6
    167410-63-1 167410-65-3 167410-67-5 167410-69-7 174891-29-3
    174892-31-0 174892-57-0 174892-58-1 186138-04-5 186138-08-9
    202475-38-5 202475-41-0 202475-44-3 202475-49-8 202475-51-2
    202475-54-5 202475-55-6 202475-57-8 202475-58-9 202475-59-0
    202475-60-3 202475-61-4 202475-62-5 202475-63-6

```

202475-64-7 202475-65-8 202475-66-9 202475-67-0 202475-68-1
202475-69-2 202475-70-5 202475-71-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

IT 80449-02-1, Protein tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(inhibitors; aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

IT 62229-50-9, Epidermal growth factor

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(receptors, inhibitors; aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; GB 1543560 1979 HCAPLUS
- (2) Anon; EP 0520722 1992 HCAPLUS
- (3) Anon; WO 9220642 1992 HCAPLUS
- (4) Anon; EP 0566225 A1 1993
- (5) Anon; EP 0635498 A1 1995 HCAPLUS
- (6) Anon; WO 9523141 1995 HCAPLUS
- (7) Barker; 1985 HCAPLUS
- (8) Barker; US 5457105 1995 HCAPLUS
- (9) Barker; US 5580870 1996 HCAPLUS
- (10) Barnish; 1975 HCAPLUS
- (11) Barnish; US 3971783 1976
- (12) Budesinsky; 1977 HCAPLUS
- (13) Byford; 1989 HCAPLUS
- (14) Cronin; 1969 HCAPLUS
- (15) Epling; 1988 HCAPLUS
- (16) Foster; US 3985749 1976 HCAPLUS
- (17) Gopinathan; 1987 HCAPLUS
- (18) Ishikura; Heterocycles 1985, V23(9), P2375 HCAPLUS
- (19) Kobayashi; US 4322420 1982 HCAPLUS
- (20) Kobayashi; US 4464375 1984 HCAPLUS
- (21) Kreighbaum; US 4343940 1982 HCAPLUS
- (22) Lederer; 1976 HCAPLUS
- (23) Leshner; US 4465686 1984 HCAPLUS
- (24) Leshner; US 4599423 1986 HCAPLUS
- (25) Lin; 1982 HCAPLUS
- (26) Marquis; 1972 HCAPLUS
- (27) Saeed; J Heterocyclic Chem 1983, V20, P1739 HCAPLUS
- (28) Shen; US 3718743 1973 HCAPLUS
- (29) Stern; J Am Chem Soc 1989, V111(3), P877 HCAPLUS
- (30) Takase; 1993 HCAPLUS
- (31) Takase; J Med Chem 1994, V37, P2106 HCAPLUS
- (32) Tamano; Tetrahedron 1982, V38(22), P3347
- (33) Witzel; US 3715358 1973
- (34) Yamamoto; Chem Pharm Bull 1982, V30(6), P2003 HCAPLUS
- (35) Yamamoto; Synthesis 1986, P564 HCAPLUS
- (36) Yoshina; 1976 HCAPLUS
- (37) Young; US 4661499 1987 HCAPLUS


IT 202475-60-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(aryl and heteroaryl quinazoline compds. which inhibit EGF and/or PDGF receptor tyrosine kinase)

RN 202475-60-3 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L40 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 1997:165787 HCAPLUS
 DN 126:264049
 TI The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56lck and EGF-R tyrosine kinase activity
 AU Myers, Michael R.; Setzer, Natalie N.; Spada, Alfred P.; Zulli, Allison L.; Hsu, Chin-Yi J.; Zilberstein, Asher; Johnson, Susan E.; Hook, Linda E.; Jacoski, Mary V.
 CS Deps. Med. Chem., Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA, 19426-0107, USA
 SO Bioorganic & Medicinal Chemistry Letters (1997), 7(4), 417-420
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 7
 GI



AB The authors report herein their preliminary results of a SAR study of quinazoline-based inhibitors of p5lck and EGF-R tyrosine kinase. The most potent inhibitor of p56lck identified, RPR-108518A [I, R1 = 3,4,5-(MeO)3C6H2, X = NH], has an IC50 of 0.50 .mu.M. The 3-chlorophenoxy- and 3-chlorothiophenoxy- derivs. I (R1 = 3-ClC6H4, X = O, S) were also shown to be extremely potent EGF-R inhibitors.
 ST anilinoquinazoline prepn tyrosine kinase inhibitor; phenoxyquinazoline prepn tyrosine inhibitor; thiophenoxyquinazoline prepn tyrosine kinase inhibitor; tyrosine kinase inhibitor anilinoquinazoline phenoxyquinazoline thiophenoxyquinazoline; quinazoline prepn tyrosine kinase inhibitor; structure activity quinazoline tyrosine kinase inhibitor
 IT Structure-activity relationship
 (enzyme-inhibiting; prepn. and tyrosine kinase inhibitory activity of

anilino-, phenoxy-, and thiophenoxy-quinazolines and structure activity)

IT 146871-70-7P 153437-07-1P 159768-25-9P 167410-34-6P 167410-65-3P
 167410-66-4P 167410-69-7P 167410-74-4P 167410-75-5P 170449-18-0P
 171744-94-8P 174892-30-9P 188829-37-0P 188829-38-1P
188829-39-2P 188829-40-5P 188829-41-6P 188829-42-7P
 188829-43-8P 188829-44-9P 188829-45-0P 188829-46-1P 188829-47-2P
 188829-48-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and tyrosine kinase inhibitory activity of anilino-, phenoxy-, and thiophenoxy-quinazolines and structure activity)

IT 80449-02-1, Tyrosine kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. and tyrosine kinase inhibitory activity of anilino-, phenoxy-, and thiophenoxy-quinazolines and structure activity)


IT **188829-39-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and tyrosine kinase inhibitory activity of anilino-, phenoxy-, and thiophenoxy-quinazolines and structure activity)

RN 188829-39-2 HCAPLUS

CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

=> fil embase medline

FILE 'EMBASE' ENTERED AT 17:11:44 ON 11 JUN 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 17:11:44 ON 11 JUN 2003

=> d all tot

L50 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 1

AN 1998352446 EMBASE

TI Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P131**) and 4-(3'-bromo- 4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (

WHI-P154).

AU Narla R.K.; Liu X.-P.; Klis D.; Uckun F.M.
 CS F.M. Uckun, Wayne Hughes Institute, 2665 Long Lake Road, St. Paul, MN
 55113, United States
 SO Clinical Cancer Research, (1998) 4/10 (2463-2471).
 Refs: 45
 ISSN: 1078-0432 CODEN: CCREF4
 CY United States
 DT Journal; Article
 FS 008 Neurology and Neurosurgery
 016 Cancer
 037 Drug Literature Index
 LA English
 SL English
 AB Glioblastoma multiforme is a highly invasive primary brain tumor with a
 disappointingly high local recurrence rate and mortality despite intensive
 multimodality treatment programs. Therefore, new agents that are capable
 of inhibiting the infiltration of normal brain parenchyma by glioblastoma
 cells are urgently needed. Here, we show that the novel quinazoline
 derivatives 4- (4 'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (**WHI-P131**) and 4-(3'- bromo-4'hydroxylphenyl)-amino-6,7-
 dimethoxyquinazoline (**WHI-P154**) are potent inhibitors
 of glioblastoma cell adhesion and migration. Specifically, both compounds
 inhibited at micromolar concentrations: (a) integrin-mediated glioblastoma
 cell adhesion to the extracellular matrix proteins laminin, type IV
 collagen, and fibronectin; (b) integrin-independent epidermal growth
 factor-induced adhesion of glioblastoma cells to poly-L-lysine-coated
 tissue culture plates; (c) fetal bovine serum-induced polymerization of
 actin and actin stress fiber formation as well epidermal growth
 factor-stimulated formation of focal adhesion plaques in serum-starved
 glioblastoma cells; and most importantly, (d) glioblastoma cell migration
 in in vitro assays of tumor cell invasiveness using tumor cell spheroids
 and/or Matrigel-coated Boyden chambers. Further preclinical development of
WHI-P131 and **WHI-P154** may provide
 the basis for the design of more effective adjuvant chemotherapy programs
 for glioblastoma multiforme.
 CT Medical Descriptors:
 *glioblastoma
 cell adhesion
 cell invasion
 cancer invasion
 cancer inhibition
 antineoplastic activity
 drug effect
 drug screening
 cell migration
 human
 controlled study
 human cell
 article
 priority journal
 Drug Descriptors:
 *4 (4' hydroxyphenyl)amino 6,7 dimethoxyquinazoline: DV, drug
 development
 *4 (4' hydroxyphenyl)amino 6,7 dimethoxyquinazoline: PD,
 pharmacology
 *4 (3' bromo 4' hydroxyphenyl)amino 6,7 dimethoxyquinazoline: DV,
 drug development
 *4 (3' bromo 4' hydroxyphenyl)amino 6,7 dimethoxyquinazoline: PD,
 pharmacology
 quinazoline derivative: DV, drug development
 quinazoline derivative: PD, pharmacology
 unclassified drug

whi p 131

whi p 154

CN Whi p 131; Whi p 154

L50 ANSWER 2 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 2
 AN 1998191566 EMBASE
 TI 4-(3'-Bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: A novel
 quinazoline derivative with potent cytotoxic activity against human
 glioblastoma cells.
 AU Narla R.K.; Liu X.-P.; Myers D.E.; Uckun F.M.
 CS F.M. Uckun, Hughes Institute, 2665 Long Lake Road, St. Paul, MN 55113,
 United States
 SO Clinical Cancer Research, (1998) 4/6 (1405-1414).
 Refs: 23
 ISSN: 1078-0432 CODEN: CCREF4
 CY United States
 DT Journal; Article
 FS 008 Neurology and Neurosurgery
 016 Cancer
 037 Drug Literature Index
 LA English
 SL English
 AB The novel quinazoline derivative 4-(3'-bromo-4'-hydroxylphenyl)-amino-
 6,7-dimethoxyquinazoline (**WHI-P154**) exhibited
 significant cytotoxicity against U373 and U87 human glioblastoma cell
 lines, causing apoptotic cell death at micromolar concentrations. The in
 vitro antiglioblastoma activity of **WHI-P154** was
 amplified >200-fold and rendered selective by conjugation to recombinant
 human epidermal growth factor (EGF). The EGF-P154 conjugate was able to
 bind to and enter target glioblastoma cells within 10-30 min via receptor
 (R)-mediated endocytosis by inducing internalization of the EGF-R
 molecules. In vitro treatment with EGF-P154 resulted in killing of
 glioblastoma cells at nanomolar concentrations with an IC50 of 813 +/-
 139 nM, whereas no cytotoxicity against EGF-R-negative leukemia cells was
 observed, even at concentrations as high as 100 .mu.M. The in vivo
 administration of EGF-P154 resulted in delayed tumor progression and
 improved tumor-free survival in a severe combined immunodeficient mouse
 glioblastoma xenograft model. Whereas none of the control mice remained
 alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and
 all control mice had tumors that rapidly progressed to reach an average
 size of >500 mm3 by 58 days, 40% of mice treated for 10 consecutive days
 with 1 mg/kg/day EGF-P154 remained alive and free of detectable tumors for
 more than 58 days with a median tumor-free survival of 40 days. The tumors
 developing in the remaining 60% of the mice never reached a size >50 mm3.
 Thus, targeting **WHI-P154** to the EGF-R may be useful in
 the treatment of glioblastoma multiforme.
 CT Medical Descriptors:
 *glioblastoma: DT, drug therapy
 *cancer cell: DT, drug therapy
 cytotoxicity
 drug potency
 antineoplastic activity
 target cell
 internalization
 cancer survival
 tumor xenograft
 gene targeting
 receptor gene
 cell death
 human
 human cell
 article
 priority journal

Drug Descriptors:

*quinazoline derivative: DO, drug dose
*quinazoline derivative: DT, drug therapy
*quinazoline derivative: PD, pharmacology
*4 (3' bromo 4' hydroxylphenyl)amino 6,7 dimethoxyquinazoline: DO,
drug dose
*4 (3' bromo 4' hydroxylphenyl)amino 6,7 dimethoxyquinazoline: DT,
drug therapy
*4 (3' bromo 4' hydroxylphenyl)amino 6,7 dimethoxyquinazoline: PD,
pharmacology
unclassified drug

=> fil biosis

FILE 'BIOSIS' ENTERED AT 17:12:54 ON 11 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 June 2003 (20030604/ED)

=> d all tot

L52 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1999:106005 BIOSIS
DN PREV199900106005
TI Structure based design of specific inhibitors of Janus kinase 3 (Jak3) as
potent anti-leukemic agents.
AU Sudbeck, E. (1); Mao, C.; Liu, X. P.; Narla, R. K.; Chen, C. L.;
Waurzyniak, B.; Uckun, F. M.
CS (1) Parker Hughes Cancer Cent., Drug Discovery Program, Dep. Structural
Biol., Hughes Inst., St. Paul, MN USA
SO Blood, (Nov. 15, 1998) Vol. 92, No. 10 SUPPL. 1 PART 1-2, pp.
599A.
Meeting Info.: 40th Annual Meeting of the American Society of Hematology
Miami Beach, Florida, USA December 4-8, 1998 The American Society of
Hematology
. ISSN: 0006-4971.
DT Conference
LA English
CC Pharmacology - General *22002
Biochemical Studies - General *10060
Blood, Blood-Forming Organs and Body Fluids - General; Methods *15001
Neoplasms and Neoplastic Agents - General *24002
General Biology - Symposia, Transactions and Proceedings of Conferences,
Congresses, Review Annuals *00520
BC Cercopithecidae 86205
Muridae 86375
IT Major Concepts
Pharmacology; Tumor Biology
IT Diseases
acute lymphoblastic leukemia: blood and lymphatic disease, neoplastic
disease
IT Chemicals & Biochemicals
anti-leukemic agents; dimethoxyquinazoline; enzyme inhibitors: structure
based designs; janus kinase 1; janus kinase 2; janus kinase 3;
WHI-P131: antineoplastic - drug, enzyme inhibitor -
drug, janus kinase 3 inhibitor
IT Alternate Indexing
Leukemia, Lymphocytic, Acute (MeSH)

IT Miscellaneous Descriptors
molecular modeling; Meeting Abstract; Meeting Poster
ORGN Super Taxa
Cercopithecidae: Primates, Mammalia, Vertebrata, Chordata, Animalia;
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
cynomolgus monkey (Cercopithecidae); mouse (Muridae): animal model
ORGN Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Primates;
Nonhuman Vertebrates; Primates; Rodents; Vertebrates
RN 9031-44-1 (KINASE)
202475-60-3 (WHI-P131)

L52 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1998:422999 BIOSIS
DN PREV199800422999
TI 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI
-P154): A novel quinazoline derivative with potent cytotoxic
activity against human glioblastoma cells.
AU Narla, R. K. (1); Liu, X.; Myers, D. E.; Venkatachalam, T.; Uckun, F. M.
CS (1) Dep. Exp. Oncol., Wayne Hughes Inst., St. Paul, MN 55113 USA
SO Abstracts of Papers American Chemical Society, (1998) Vol. 216, No. 1-3,
pp. MEDI 342.
Meeting Info.: 216th National Meeting of the American Chemical Society
Boston, Massachusetts, USA August 23-27, 1998 American Chemical Society
. ISSN: 0065-7727.
DT Conference
LA English
CC Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
Nervous System - Pathology *20506
Pharmacology - Neuropharmacology *22024
General Biology - Symposia, Transactions and Proceedings of Conferences,
Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Pharmacology; Tumor Biology
IT Chemicals & Biochemicals
4-(3'-bromo-4'-
hydroxylphenyl)-amino-6,7-
dimethoxyquinazoline [WHI-P154]:
antineoplastic - drug, novel quinazoline derivative, cytotoxic activity
IT Miscellaneous Descriptors
Meeting Abstract
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae): glioblastoma cell lines
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
RN 253-82-7D (QUINAZOLINE)

=> fil reg

FILE 'REGISTRY' ENTERED AT 17:38:18 ON 11 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7
DICTIONARY FILE UPDATES: 10 JUN 2003 HIGHEST RN 528811-66-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 158

L53 STR



VAR G1=NH/48/50/S/O/CH2/54/58

VAR G2=H/O/S/N/NO2/AK/20/24/X

VAR G3=32/7

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 12

CONNECT IS M1 RC AT 13

CONNECT IS M1 RC AT 14

CONNECT IS M1 RC AT 15

CONNECT IS M1 RC AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE



L55 3070 SEA FILE=REGISTRY CSS FUL L53

L56 STR





Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

@20
O
|
Ak
23

@24
S
|
Ak
25



@48
N
|
Ak
49



VAR G1=NH/48/50/S/O/CH2/54/58
VAR G2=H/O/S/N/NO2/AK/20/24/X
VAR G3=32/7

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 58

STEREO ATTRIBUTES: NONE

L58 1124 SEA FILE=REGISTRY SUB=L55 CSS FUL L56


100.0% PROCESSED 2908 ITERATIONS

SEARCH TIME: 00.00.01

1124 ANSWERS

=> d sta que 161

L53 STR



VAR G1=NH/48/50/S/O/CH2/54/58
 VAR G2=H/O/S/N/NO2/AK/20/24/X
 VAR G3=32/7

NODE ATTRIBUTES:


CONNECT IS M1 RC AT 12
 CONNECT IS M1 RC AT 13
 CONNECT IS M1 RC AT 14
 CONNECT IS M1 RC AT 15
 CONNECT IS M1 RC AT 17
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L55 3070 SEA FILE=REGISTRY CSS FUL L53
 L59 STR



VAR G1=NH/48/50/S/O/CH2/54/58
 VAR G2=H/O/S/N/NO2/AK/20/24/X
 VAR G3=32/7

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 GGCAT IS PCY AT 66
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE

L61 135 SEA FILE=REGISTRY SUB=L55 CSS FUL L59

100.0% PROCESSED 3070 ITERATIONS
 SEARCH TIME: 00.00.01

135 ANSWERS

=> d his 161-

(FILE 'REGISTRY' ENTERED AT 17:13:13 ON 11 JUN 2003)
 L61 135 S L59 CSS FUL SUB=L55
 SAV L61 HOPE345B/A
 L62 1237 S L58,L61 NOT L8,L9

FILE 'HCAOLD' ENTERED AT 17:26:19 ON 11 JUN 2003
 L63 20 S L62

FILE 'REGISTRY' ENTERED AT 17:27:06 ON 11 JUN 2003
 L64 73 S L62 AND CAOLD/LC

FILE 'HCAPLUS' ENTERED AT 17:27:33 ON 11 JUN 2003

L65 389 S L62
L66 18 S L65 AND L1
L67 18 S L65 AND (HUGHES? OR PARKER? OR WAYNE?)/PA,CS
L68 18 S L66,L67
L69 9 S L65 AND L24
L70 6 S L65 AND (JANUSKINASE OR JANUS KINASE)
L71 5 S L65 AND (CJUN OR C JUN)
L72 218 S L65 AND (PD<=19980630 OR PRD<=19980630 OR AD<=19980630)
L73 2 S L72 AND L68
L74 1 S L72 AND L69-L71
L75 3 S L73,L74
L76 207 S L65 AND PY<=1998
L77 0 S L76 AND L69-L71
L78 218 S L72,L76
E GLIOBLASTOMA/CT
E E3+ALL
L79 2709 S E2
L80 579 S E6
L81 4355 S ?GLIOBLASTOM?
E NEUROGLIA/CT
E E3+ALL
L82 31326 S E5+NT
E BRAIN NEOPLASM/CT
E E4+ALL
E E2+ALL
L83 4860 S E7,E6+NT
L84 9 S L78 AND L79-L83
L85 3 S L78 AND BRAIN(L) (?CANCER? OR ?TUMOR? OR ?NEOPLAS? OR ?MALIGN
L86 10 S L84,L85,L75
E ANTITUMOR/CT
E E5+ALL
L87 158675 S E4,E3,E20-E26
L88 30685 S E28+NT OR E29+NT OR E30+NT
L89 214899 S E31+NT
L90 73 S L78 AND L87-L89
L91 9 S L90 AND L86
L92 10 S L86,L91

FILE 'REGISTRY' ENTERED AT 17:38:18 ON 11 JUN 2003

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:38:38 ON 11 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2003 VOL 138 ISS 24

FILE LAST UPDATED: 10 Jun 2003 (20030610/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 192 all hitstr tot

L92 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:906210 HCAPLUS

DN 136:15231

TI Methods using a tyrosine kinase inhibitor to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors

IN Huang, H.-J. Su; Nagane, Motoo; Cavenee, Webster K.; Levitzki, Alexander; Gazit, Aviv

PA USA

SO U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-33

ICS A61K031-505; A61K033-24; C07D239-00; C07D491-00; A61K031-44

NCL 514259000

CC 1-6 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001051628	A1	20011213	US 1998-71541	19980504 <--
PRAI	US 1998-71541		19980504 <--		

AB Methods and compns. are provided for enhancing the activity of various therapeutic agents that induce apoptosis by modulating the apoptosis-inhibiting effects of the expression products of mutant epidermal growth factor receptor (EGFR) genes. Methods and compns. of particular use in the treatment of cancers, e.g. glioma, that express such a mutant EGFR gene are provided. The methods of the invention use a tyrosine kinase inhibitor (e.g. tyrphostin AG1478) in combination with an apoptosis-inducing therapeutic agent (e.g. cisplatin).

ST antitumor tyrosine kinase inhibitor apoptosis agent; EGF receptor cancer apoptosis tyrosine kinase inhibitor antitumor agent; tyrphostin AG1478 cisplatin antitumor glioma

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bcl-xL; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study) (EGF receptor; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Epidermal growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Neuroglia

(glioma, inhibitors; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Antitumor agents

(glioma; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Lung, neoplasm

Ovary, neoplasm


(inhibitors; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Antitumor agents


(lung; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)

IT Antitumor agents

- (mammary gland; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT Mammary gland
(neoplasm, inhibitors; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT **Antitumor agents**
(ovary; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT Drug interactions
(synergistic; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT **Antitumor agents**
Apoptosis
Drug delivery systems
Drug resistance
(tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT 169592-56-7, Caspase-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-like; tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT 79079-06-4, EGF receptor tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT 57-22-7, Vincristine 15663-27-1, Cisplatin 33069-62-4, Paclitaxel 153436-53-4, Tyrphostin AG 1478 153436-53-4D, Tyrphostin AG 1478, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- IT 153436-53-4, Tyrphostin AG 1478 153436-53-4D, Tyrphostin AG 1478, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tyrosine kinase inhibitor to modulate resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors)
- RN 153436-53-4 HCAPLUS
CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



- RN 153436-53-4 HCAPLUS
CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L92 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:764027 HCAPLUS
 DN 132:9009
 TI Quinazolines and conjugates thereof for treating **brain tumors**
 IN Uckun, Fatih M.; Narla, Rama K.; Liu, Xing-Ping
 PA Wayne Hughes Institute, USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D239-94
 ICS C07D239-88; C07D239-74; A61K031-505
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 2, 28, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961428	A1	19991202	WO 1999-US11767	19990528 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2333392	AA	19991202	CA 1999-2333392	19990528 <--
	AU 9943173	A1	19991213	AU 1999-43173	19990528 <--
	EP 1082311	A1	20010314	EP 1999-953336	19990528 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002516823	T2	20020611	JP 2000-550834	19990528 <--
	US 6316454	B1	20011113	US 1999-361088	19990726 <--
	NO 2000005864	A	20010129	NO 2000-5864	20001120 <--
	US 2002161226	A1	20021031	US 2001-903294	20010711
	US 6552027	B2	20030422		
PRAI	US 1998-87479	A	19980529	<--	
	WO 1999-US11767	W	19990528		
	US 1999-361088	A1	19990726		

OS MARPAT 132:9009

AB Substituted quinazoline compds. and conjugates useful for inhibiting the growth of **brain tumor** cells and for inhibiting adhesion and migration of **brain tumor** cells are provided. The compds. include 4-(3'-bromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline and this compd. covalently bound to e.g. EGF.

ST quinazoline deriv **brain cancer** treatment; EGF
 quinazoline conjugate **brain cancer** treatment; adhesion

- brain cancer** cell quinazoline deriv; migration
brain cancer cell quinazoline deriv
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to, conjugates; quinazoline derivs., prepn., conjugates,
and use for treating **brain tumors**)
- IT Structure-activity relationship
(**antitumor**; quinazoline derivs., prepn., conjugates, and use
for treating **brain tumors**)
- IT **Antitumor agents**
Antitumor agents
(**brain**; quinazoline derivs., prepn., conjugates, and use for
treating **brain tumors**)
- IT Antibodies
Cytokines
Growth factors, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(conjugates; quinazoline derivs., prepn., conjugates, and use for
treating **brain tumors**)
- IT **Neuroglia**
(**glioblastoma**, cell adhesion; quinazoline derivs., prepn.,
conjugates, and use for treating **brain tumors**)
- IT **Neuroglia**
Neuroglia
(**glioblastoma**, inhibitors; quinazoline derivs., prepn.,
conjugates, and use for treating **brain tumors**)
- IT **Antitumor agents**
(**glioblastoma**; quinazoline derivs., prepn., conjugates, and
use for treating **brain tumors**)
- IT **Brain, neoplasm**
Brain, neoplasm
(inhibitors; quinazoline derivs., prepn., conjugates, and use for
treating **brain tumors**)
- IT **Brain, neoplasm**
(**medulloblastoma**, cell adhesion; quinazoline derivs., prepn.,
conjugates, and use for treating **brain tumors**)
- IT **Antitumor agents**
(**metastasis**; quinazoline derivs., prepn., conjugates, and use
for treating **brain tumors**)
- IT Actins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(polymn.; quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)
- IT Apoptosis
Cell adhesion
Cell migration
Drug delivery systems
Drug targeting
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)
- IT Epidermal growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)
- IT Biological transport
(uptake; quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)
- IT 211555-04-3DP, WHI-P154, EGF conjugates
RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)

IT 62229-50-9, Epidermal growth factor
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)

IT 21561-09-1P, WHI-P 258 153436-54-5P, WHI-P 79
202475-60-3P, WHI-P131 211555-04-3P, WHI-P154 211555-05-4P,
WHI-P 97 211555-06-5P, WHI-P 111 211555-07-6P, WHI-P
132 211555-08-7P, WHI-P180 211555-09-8P, WHI-P 197
251376-04-2P, WHI-P 292
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)


IT 62229-50-9D, Epidermal growth factor, quinazoline deriv. conjugates
202475-60-3D, WHI-P131, EGF conjugates 251347-48-5
251347-49-6 251347-50-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)

IT 62-53-3, Benzenamine, reactions 95-55-6, 2-Hydroxyaniline 123-30-8,
4-Hydroxyaniline 591-19-5, 3-Bromoaniline 591-27-5, 3-Hydroxyaniline
609-21-2, 3,5-Dibromo-4-hydroxyaniline 2834-92-6 3964-52-1,
3-Chloro-4-hydroxyaniline 7745-91-7, 3-Bromo-4-methylaniline
13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline 16750-67-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; quinazoline derivs., prepn., conjugates, and use for
treating **brain tumors**)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Narla, R; Clinical Cancer Research 1998, V4(6), P1405 HCAPLUS
(2) Rhone-Poulenc; WO 9515758 A 1995 HCAPLUS
(3) Zeneca; EP 0566226 A 1993 HCAPLUS
(4) Zeneca; WO 9615118 A 1996 HCAPLUS
(5) Zeneca; WO 9730035 A 1997 HCAPLUS
(6) Zeneca; WO 9732856 A 1997 HCAPLUS


IT 21561-09-1P, WHI-P 258 153436-54-5P, WHI-P 79
211555-05-4P, WHI-P 97 211555-06-5P, WHI-P 111
211555-07-6P, WHI-P 132 211555-08-7P, WHI-P180
211555-09-8P, WHI-P 197 251376-04-2P, WHI-P 292
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazoline derivs., prepn., conjugates, and use for treating
brain tumors)

RN 21561-09-1 HCAPLUS
CN 4-Quinazolinamine, 6,7-dimethoxy-N-phenyl- (9CI) (CA INDEX NAME)




RN 153436-54-5 HCAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 211555-05-4 HCAPLUS

CN Phenol, 2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-06-5 HCAPLUS

CN 4-Quinazolinamine, N-(3-bromo-4-methylphenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 211555-07-6 HCAPLUS

CN Phenol, 2-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-08-7 HCAPLUS

CN Phenol, 3-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-09-8 HCAPLUS

CN Phenol, 2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 251376-04-2 HCAPLUS

CN 2-Naphthalenol, 3-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




IT 251347-48-5 251347-49-6 251347-50-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quinazoline derivs., prepn., conjugates, and use for treating brain tumors)


RN 251347-48-5 HCAPLUS

CN 2-Naphthalenol, 1-[(6,7-dimethoxy-4-quinazolinyl)amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 251347-49-6 HCAPLUS

CN 2-Naphthalenol, 1-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 251347-50-9 HCAPLUS
 CN Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluoro- (9CI) (CA INDEX NAME)




L92 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:718981 HCAPLUS
 DN 131:322425
 TI Preparation of phenylacrylonitriles, quinoxalines, quinazolines, and related compounds as modulators of tyrosine kinase signal transduction
 IN App, Harald; McMahon, Gerald M.; Tang, Peng Cho; Gazit, Aviv; Levitzki, Alexander
 PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel; Sugen, Inc.
 SO U.S., 21 pp., Cont.-in-part of U.S. 5,712,395.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-275
 ICS A61K031-40; A61K031-415; C07C317-28
 NCL 514419000
 CC 25-20 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1, 28
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5981569	A	19991109	US 1995-463247	19950605 <--
	CA 2149298	AA	19940526	CA 1993-2149298	19931115 <--
	US 6177401	B1	20010123	US 1994-193829	19940209 <--
	US 5712395	A	19980127	US 1995-386021	19950209 <--
PRAI	US 1992-975750	B2	19921113		<--
	US 1993-38596	B2	19930326		<--
	US 1994-193829	A2	19940209		<--


US 1995-386021 A2 19950209 <--
 OS MARPAT 131:322425
 GI



I



II




III

- AB Title compds., e.g., [I, II, III; R1 = Me2CH, Me3C, iodo, Br, OH, Me; R2 = OH; R3 = Me2CH, Me3C, OH, H, Me; R4 = 1-phenyl-n-propylaminocarbonyl, (E)-1-cyano-2-[(3,5-diisopropyl-4-hydroxy)phenyl]ethenylsulfonyl, aminothiocabonyl, cyanomethylsulfonyl, (3-amino-4-cyano)pyrazol-4-yl, etc.; R5, R6 = H, Me; R7 = H, CHO, Cl; R8 = Ph, 3,4-dihydroxyphenyl, 4-iodophenylamino, 3-chlorophenylamino, etc.; R9 = H, Me, OMe; R10 = H, OMe; R11 = H, Cl; R12 = 3-chlorophenylamino, 4-methylphenylmercapto, 4-iodophenylamino, 3-hydroxyphenylamino], were prepd. as modulators of KDR/FLK-1 receptor signal transduction useful to regulate and/or modulate vasculogenesis and angiogenesis. Thus, 3,5-di-tert-butyl-4-hydroxybenzaldehyde, thiocyanacetamide, and .beta.-alanine were refluxed 6 h in EtOH to give (E)-2-aminothiocarbonyl-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylonitrile. The latter showed IC50 = 0.8 .mu.M in an in vitro FLK-1R ELISA assay.
- ST phenylacrylonitrile quinoxaline quinazoline prepn tyrosine kinase signal transduction modulator; anticancer phenylacrylonitrile quinoxaline quinazoline; antidiabetic phenylacrylonitrile quinoxaline quinazoline; KDR FLK1 receptor signal transduction modulator phenylacrylonitrile quinoxaline quinazoline; vasculogenesis modulator phenylacrylonitrile quinoxaline quinazoline; angiogenesis modulator phenylacrylonitrile quinoxaline quinazoline
- IT **Sarcoma**
 (Kaposi's, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Intestine, neoplasm
 (colon, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Eye, disease
 (diabetic retinopathy, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT **Neuroglia**
 (glioma, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Blood vessel, neoplasm
 (hemangioma, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Angiogenesis
 (modulators; prepn. of phenylacrylonitriles and related compds. as


- modulators of tyrosine kinase signal transduction)
- IT Prostate gland
(neoplasm, treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Antidiabetic agents
Antitumor agents
(prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Vascular endothelial growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT Lung, neoplasm
Melanoma
Ovary, neoplasm
Pancreas, neoplasm
Skin, neoplasm
(treatment; prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT 133550-18-2P 140674-76-6P 140674-77-7P 148741-30-4P 148741-31-5P
155566-32-8P 168835-80-1P 168835-82-3P 168835-83-4P 168835-85-6P
168835-87-8P 168835-88-9P 168835-89-0P 168835-90-3P
168835-91-4P 168835-92-5P 168835-93-6P
168835-94-7P 168835-95-8P 168835-96-9P 168835-97-0P
168835-98-1P 168836-00-8P 168836-01-9P 168836-02-0P 169120-56-3P
170448-92-7P 211370-16-0P 249296-58-0P **249296-59-1P**
249296-66-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT 75-12-7, Formamide, reactions 95-76-1, 3,4-Dichloroaniline 99-40-1
100-46-9, Benzylamine, reactions 106-40-1, p-Bromoaniline 106-45-6,
p-Thiocresol 107-95-9, .beta.-Alanine 108-42-9 109-77-3,
Malononitrile 123-08-0, 4-Hydroxybenzaldehyde 139-85-5,
3,4-Dihydroxybenzaldehyde 298-12-4, Glyoxylic acid 491-36-1,
4-Quinazoline 540-37-4, p-Iodoaniline 591-27-5 626-01-7,
3-Iodoaniline 771-97-1, 2,3-Diaminonaphthalene 1074-12-0,
Phenylglyoxal 1194-98-5, 2,5-Dihydroxybenzaldehyde 1196-69-6,
5-Formylindole 1620-98-0, 3,5-Di-tert-butyl-4-hydroxybenzaldehyde
1960-77-6 2078-54-8, 2,6-Diisopropylphenol 2740-81-0, 2-Chlorophenyl
isothiocyanate 2941-78-8, 5-Methyl-2-aminobenzoic acid 3171-45-7,
4,5-Dimethyl-1,2-diaminobenzene 3216-88-4 5438-36-8, 5-Iodovanillin
5653-40-7, 4,5-Dimethoxy-2-aminobenzoic acid. 7357-70-2 10412-93-8,
N-Benzylcyanoacetamide 10537-86-7 16414-34-9, 5-Bromo-3,4-
dihydroxybenzaldehyde 28888-44-0, 6,7-Dimethoxy-2,4-quinazolinedione
37463-94-8 54711-21-6 58421-79-7, 4-Chloro-6-methylquinazoline
70071-08-8 93071-65-9, Methyl 3-aminomethylbenzoate 111233-69-3
133550-33-1 133550-57-9 168836-05-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- IT 5190-68-1P 13790-39-1P 13794-72-4P 19181-53-4P 27389-84-0P
27631-29-4P 28082-82-8P 29067-81-0P 168835-79-8P 170449-31-7P
170449-32-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Anon; DE 1135471 1962 HCAPLUS
 - (2) Anon; JP 55-167205 1980 HCAPLUS
 - (3) Anon; EP 322738 1989 HCAPLUS
 - (4) Anon; WO 9115495 1991 HCAPLUS
 - (5) Anon; EP 0520722 A1 1992 HCAPLUS
 - (6) Anon; WO 9203459 1992 HCAPLUS
 - (7) Anon; WO 9214748 1992 HCAPLUS
 - (8) Anon; WO 9217486 1992 HCAPLUS
 - (9) Anon; WO 9220642 1992 HCAPLUS
 - (10) Anon; WO 9221660 1992 HCAPLUS
 - (11) Anon; EP 0566226 A1 1993 HCAPLUS
 - (12) Anon; WO 9403427 1994 HCAPLUS
 - (13) Anon; WO 9410202 1994 HCAPLUS
 - (14) Anon; WO 9414808 1994 HCAPLUS
 - (15) Anon; WO 9426260 1994 HCAPLUS
 - (16) Anon; WO 9514464 1995 HCAPLUS
 - (17) Anon; WO 9519169 1995 HCAPLUS
 - (18) Anon; WO 9521613 1995 HCAPLUS
 - (19) Cho; US 5063243 1991 HCAPLUS
 - (20) Dell; US 5281619 1994 HCAPLUS
 - (21) Eissenstat; US 5330992 1994 HCAPLUS
 - (22) Gazit, A; J Med Chem 1993, V36, P3556 HCAPLUS
 - (23) Gazit, A; Journ Med Chem 1991, V34, P1896 HCAPLUS
 - (24) Green; US 5124354 1992 HCAPLUS
 - (25) Kokosi, J; 1990 HCAPLUS
 - (26) Levitzki; US 5217999 1993 HCAPLUS
 - (27) Mazumder; Biochemistry 1995, V34(46), P15111 HCAPLUS
 - (28) Merlin, J; Can J Chem 1985, V63, P1840 HCAPLUS
 - (29) Miyoshi, H; Biochimica et Biophysica Acta 1988, V935, P312 HCAPLUS
 - (30) Ohmichi; Biochemistry 1993, V32(17), P4650 HCAPLUS
 - (31) Ohmichi, M; Biochemistry 1993, V32, P4650 HCAPLUS
 - (32) Posner; Molecular Pharmacology 1994, V45(4), P673 HCAPLUS
 - (33) Spada; US 5302606 1994 HCAPLUS
 - (34) Vallee; US 4966849 1990 HCAPLUS
 - (35) Yaish; Science 1988, V242(4880), P933 HCAPLUS
- IT 168835-91-4P 168835-92-5P 168835-94-7P
 168835-96-9P 249296-59-1P 249296-66-0P
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (prepn. of phenylacrylonitriles and related compds. as modulators of tyrosine kinase signal transduction)
- RN 168835-91-4 HCAPLUS
- CN 4-Quinazolinamine, N-(4-iodophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 168835-92-5 HCAPLUS

CN Phenol, 3-[(6-methyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 168835-94-7 HCAPLUS

CN Phenol, 3-(4-quinazolinylamino)- (9CI) (CA INDEX NAME)




RN 168835-96-9 HCAPLUS

CN 4-Quinazolinamine, 2-chloro-N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 249296-59-1 HCAPLUS

CN Quinazoline, 6-methyl-4-[(4-methylphenyl)thio]- (9CI) (CA INDEX NAME)



RN 249296-66-0 HCAPLUS
 CN Phenol, 3-[(6-methyl-4-quinazolinyl)amino]-, hydrochloride (9CI) (CA
 INDEX NAME)



●x HCl

L92 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:659226 HCAPLUS
 DN 131:281600
 TI Methods and compositions for reducing UV-induced inhibition of collagen
 synthesis in human skin
 IN Fisher, Gary J.; Voorhees, John J.
 PA The Regents of the University of Michigan, USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-20
 ICS A61K031-12; A61K031-235; A61K031-35; A61K031-17
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 62, 63
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951220	A1	19991014	WO 1999-US7267	19990402 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2326507	AA 19991014	CA 1999-2326507	19990402 <--
AU 9936374	A1 19991025	AU 1999-36374	19990402 <--
AU 740569	B2 20011108		
BR 9909899	A 20001226	BR 1999-9899	19990402 <--
EP 1067920	A1 20010117	EP 1999-918456	19990402 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

JP 2002510621	T2 20020409	JP 2000-541991	19990402 <--
---------------	-------------	----------------	--------------

PRAI US 1998-80437P P 19980402 <--
 WO 1999-US7267 W 19990402

AB Exposure of human skin to UV (UV) radiation from the sun not only induces the prodn. of enzymes (matrix metalloproteinases) that degrade collagen, but also inhibits the synthesis of new collagen by inhibiting the synthesis of procollagen. This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or **c-JUN** inhibitor to the skin prior to its exposure to UV radiation. It was shown that retinoids such as retinoic acid protect human skin in vivo against the UV-induced inhibition of collagen synthesis.

ST UV inhibition collagen synthesis retinoid

IT Ionophores
 (antagonists; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT G proteins (guanine nucleotide-binding proteins)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (**c-jun**; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Collagens, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (procollagens; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Antioxidants
 Skin
 Sunscreens
 UV radiation
 (retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Collagens, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Retinoids
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT Drug delivery systems
 (topical; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT 62229-50-9, Egf
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT 100324-81-0, Lisofylline 152121-30-7, SB202190 167869-21-8, PD98059
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(c-JUN inhibitor; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT 37277-79-5, Geranyltransferase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor; retinoids for reducing UV-induced inhibition of collagen synthesis in human skin)

IT 145-63-1, Suramin 446-72-0, Genistein 2826-26-8, Tyrphostin 1
 118409-57-7, Tyrphostin 23 118409-59-9, Tyrphostin 46 118409-60-2,
 Tyrphostin 47 125697-92-9, Lavendustin A 126433-07-6, Tyrphostin 51
 133550-35-3, AG-494 **153436-54-5**, PD 153035
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ionophore or G-protein or EGF receptor antagonist; retinoids for
 reducing UV-induced inhibition of collagen synthesis in human skin)

IT 100827-28-9D, Erbstatin, analogs
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ionophore or G-protein or EGF receptor antagonists; retinoids for
 reducing UV-induced inhibition of collagen synthesis in human skin)

IT 68-26-8, Retinol 302-79-4, Retinoic acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (retinoids for reducing UV-induced inhibition of collagen synthesis in
 human skin)

IT 5466-77-3, 2-Ethylhexyl p-methoxycinnamate 70356-09-1,
 4-tert-Butyl-4'-methoxydibenzoylmethane
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (sunscreen; retinoids for reducing UV-induced inhibition of collagen
 synthesis in human skin)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Habif; US 5690947 A 1997 HCAPLUS
 (2) Kligman; US 5051449 A 1991 HCAPLUS
 (3) Murray; US 4810489 A 1989 HCAPLUS
 (4) Wei; US 5824702 A 1998 HCAPLUS

IT **153436-54-5**, PD 153035
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ionophore or G-protein or EGF receptor antagonist; retinoids for
 reducing UV-induced inhibition of collagen synthesis in human skin)

RN 153436-54-5 HCAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L92 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1998:534888 HCAPLUS
 DN 129:156926
 TI Methods and compositions using receptor tyrosine kinase inhibitors for
 inhibiting cell proliferative disorders, and inhibitor preparation
 IN Chen, Hui; Gazit, Aviv; Hirth, Klaus Peter; Mann, Elaina; Shawver, Laura

K.; Tsai, Jianming; Tang, Peng Cho
 PA Sugen, Inc., USA; Yisum Research & Development Company of the Hebrew
 University of Jerusalem
 SO U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 207,933, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A01N043-40
 ICS C07D211-72
 NCL 514352000
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 25, 28, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5789427	A	19980804	US 1995-399967	19950307 <--
	US 5773476	A	19980630	US 1995-486775	19950607 <--
PRAI	US 1994-207933		19940307	<--	
	US 1995-399967		19950307	<--	
OS	MARPAT 129:156926				
AB	The invention concerns compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders, e.g. cancers characterized by over-activity or inappropriate activity HER2 or EGFR.				
ST	receptor tyrosine kinase inhibitor prepn antiproliferative; antitumor receptor tyrosine kinase inhibitor prepn; HER2 EGFR kinase inhibitor antiproliferative antitumor				
IT	Animal cell line (A431; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Ovary, neoplasm Salivary gland Salivary gland Salivary gland Stomach, neoplasm Stomach, neoplasm (adenocarcinoma, inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Mammary gland (carcinoma, inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Receptors RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (chimeric, EGFR-HER2; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Intestine, neoplasm Intestine, neoplasm (colorectal, inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Antitumor agents Antitumor agents (colorectal; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Uterus, neoplasm Uterus, neoplasm (endometrium, inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				
IT	Antitumor agents Antitumor agents (endometrium; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)				

- IT **Antitumor agents**
Antitumor agents
(gastric adenocarcinoma; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Neuroglia**
(**glioblastoma**, inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(**glioblastoma**; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT Ovary, neoplasm
Stomach, neoplasm
(inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(mammary gland carcinoma; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(ovary adenocarcinoma; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(ovary; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT Proliferation inhibition
(proliferation inhibitors; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
Cytotoxic agents
Drug delivery systems
(receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT Epidermal growth factor receptors
Growth factor receptors
neu (receptor)
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT Platelet-derived growth factor receptors
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(salivary gland adenocarcinoma; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT **Antitumor agents**
(stomach; receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT 1960-77-6P 5190-68-1P, 4-Chloroquinazoline 10537-86-7P,
3,5-Diisopropyl-4-hydroxybenzaldehyde 19181-54-5P 27389-84-0P
29634-62-6P 170449-31-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

IT 93-91-4, Benzoyl acetone 94-02-0, Ethyl benzoyl acetate 98-16-8
99-40-1 100-46-9, Benzylamine, reactions 103-79-7, Phenyl acetone
105-34-0, Methyl cyanoacetate 108-42-9, 3-Chloroaniline 109-76-2,
1,3-Propanediamine 109-77-3, Malononitrile 109-80-8,

1,3-Propanedithiol 120-46-7, Dibenzoyl methane 123-54-6,
 2,4-Pentanedione, reactions 139-85-5, 3,4-Dihydroxybenzaldehyde
 480-96-6, Benzofuroxane 485-47-2, Ninhydrin 491-36-1, 4-Quinazolinone
 579-07-7 868-54-2, Malononitrile dimer 1075-06-5, Phenyl glyoxal
 hydrate 1194-98-5, 2,5-Dihydroxybenzaldehyde 1620-98-0,
 3,5-Di-tert-butyl-4-hydroxybenzaldehyde 2038-57-5, 3-Phenylpropylamine
 2078-54-8, 2,6-Diisopropylphenol 2423-66-7 2941-78-8,
 5-Methyl-2-aminobenzoic acid 3171-45-7 4389-45-1, 2-Amino-3-
 methylbenzoic acid 4518-10-9 5348-42-5, 4,5-Dichloro-1,2-
 phenylenediamine 5438-36-8, 5-Iodovanillin 7357-70-2 10412-93-8,
 N-Benzylcyanoacetamide 13790-39-1, 4-Chloro-6,7-dimethoxyquinazoline
 14268-66-7, 3,4-Methylenedioxyaniline 16414-34-9, 3,4-Dihydroxy-5-
 bromobenzaldehyde 24522-30-3 27869-04-1 37463-94-8 40018-25-5,
 2-Chlorobenzoylacetonitrile 54711-21-6 58421-79-7,
 4-Chloro-6-methylquinazoline 74908-81-9 133550-33-1 138942-61-7
 168835-79-8 170449-33-9 170449-34-0, 2-Pyridinesulfonylacetonitrile
 RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction; receptor tyrosine kinase inhibitors, and prepn. thereof, for
 inhibiting cell proliferative disorders)

IT 79079-06-4, EGF receptor tyrosine kinase 127407-08-3, Receptor tyrosine
 kinase 137632-09-8, HER2 kinase

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BPR (Biological process); BSU (Biological
 study, unclassified); BIOL (Biological study); PROC (Process)

(receptor tyrosine kinase inhibitors, and prepn. thereof, for
 inhibiting cell proliferative disorders)

IT 101463-26-7

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); BIOL (Biological study);
 PROC (Process)

(receptor tyrosine kinase inhibitors, and prepn. thereof, for
 inhibiting cell proliferative disorders)

IT 13494-38-7P 65224-45-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)

(receptor tyrosine kinase inhibitors, and prepn. thereof, for
 inhibiting cell proliferative disorders)

IT 555-60-2P 5023-53-0P 5784-78-1P 6639-86-7P 10537-47-0P

13297-17-1P 15034-21-6P 23190-84-3P 40114-83-8P 54259-09-5P

57859-60-6P 70071-08-8P 71896-95-2P **88404-44-8P**

140674-76-6P **146871-70-7P** 148741-30-4P 148741-31-5P

148741-32-6P **153436-53-4P** 168835-82-3P 168835-87-8P

170448-89-2P 170448-90-5P 170448-91-6P 170448-92-7P 170449-00-0P

170449-12-4P 170449-13-5P **170449-14-6P 170449-15-7P**

170449-16-8P 170449-17-9P 170449-18-0P

170449-19-1P 170449-20-4P 170449-21-5P 170449-22-6P

170449-23-7P 170449-24-8P 170449-25-9P 211298-73-6P 211298-75-8P

211298-81-6P 211298-83-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(receptor tyrosine kinase inhibitors, and prepn. thereof, for
 inhibiting cell proliferative disorders)

IT 65678-07-1 133550-41-1 170448-88-1 170448-95-0 170448-97-2

170448-98-3 170448-99-4 170449-02-2 170449-03-3 170449-04-4

170449-05-5 170449-06-6 170449-07-7 170449-08-8 170449-11-3

170449-26-0 170449-27-1 170449-28-2 170449-29-3 170449-30-6

186581-94-2 186581-95-3 186581-96-4 211299-44-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)


- (receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- IT 15762-68-2P 19181-53-4P, 6-Methyl-4-quinazolinone 58421-80-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)
- RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Aaronson, S; Science 1991, V254, P1146 HCAPLUS
 - (2) Affleck; Proc Annun Meeting American Associate Cancer Research 1993, V34, PA2298
 - (3) Anafi; J Bio Chem 1992, V267, P4518 HCAPLUS
 - (4) Andrews; J American Veterinary Medicine Association 1993, V202(2), P229
 - (5) Anon; GB 1191306 1970 HCAPLUS
 - (6) Anon; GB 2240104 1991 HCAPLUS
 - (7) Anon; EP 0520722 1992 HCAPLUS
 - (8) Anon; CA 2069857 1992 HCAPLUS
 - (9) Anon; WO 9202444 1992
 - (10) Anon; WO 9203736 1992 HCAPLUS
 - (11) Anon; EP 0537742 1993 HCAPLUS
 - (12) Anon; EP 0566226 1993 HCAPLUS
 - (13) Anon; AU 3101093 1993
 - (14) Anon; WO 9426260 1994 HCAPLUS
 - (15) Anon; WO 9524190 1995 HCAPLUS
 - (16) Baselga; J of Natl Cancer Institute 1993, V85(16), P1327 HCAPLUS
 - (17) Bilder; Am J Physiol, Cell Physiol 29 1991, V260, PC721 HCAPLUS
 - (18) Birchall; 1978 HCAPLUS
 - (19) Bryckaert; Exp Cell Research 1992, V199, P255 HCAPLUS
 - (20) Caraglia; Cancer Immunol Immunother 1993, V37, P150 HCAPLUS
 - (21) Carboni; J Am Chem Soc 1958, V80, P2838 HCAPLUS
 - (22) Carraway; Cell 1994, V78, P5 HCAPLUS
 - (23) Carraway; J Biol Chem 1994, V269, P14303 HCAPLUS
 - (24) Dati; Oncogene 1990, V5, P1001 HCAPLUS
 - (25) Decker; J Immunol Methods 1988, V15, P61
 - (26) Dougall; Oncogene 1994, V9, P2109 HCAPLUS
 - (27) Dressler; US 3313771 1967 HCAPLUS
 - (28) Ferris; J Org Chem 1979, V44(2), P173 HCAPLUS
 - (29) Floege; Kidney International 1993, V43S, P47
 - (30) Gazit; J Med Chem 1989, V32, P2344 HCAPLUS
 - (31) Gazit; J Med Chem 1993, V36, P3556 HCAPLUS
 - (32) Gazit; J Med- Chem 1991, V34, P1896 HCAPLUS
 - (33) Gottardis; J Steriod Biochem 1988, V30(1-6), P331
 - (34) Hale; J Clin Pathol 1993, V46, P149 MEDLINE
 - (35) Harris; New England J of Medicine 1992, V327(5), P319 MEDLINE
 - (36) Hoekstra; Experimental Therapeutics from 84th Annual Meeting of American Association for Cancer Research 1993, V34(2455)
 - (37) Honegger; Cell 1987, V5, P199
 - (38) Hudziak; Molecular and Cellular Biology 1989, V9, P1165 HCAPLUS
 - (39) Issidorides; J Org Chem 1966, V31, P4067 HCAPLUS
 - (40) Karameris; Path Res Pract 1993, V189, P133 MEDLINE
 - (41) Koenders; Breast Cancer Research and Treatment 1993, V25, P21 MEDLINE
 - (42) Korzeniewski; J Immunol Methods 1983, V64, P313 HCAPLUS
 - (43) Lee; J Org Chem 1975, V40(24), P3608 HCAPLUS
 - (44) Levitzki; US 5217999 1993 HCAPLUS
 - (45) Levitzki, A; Biochem Pharm 1990, V40(5), P913 HCAPLUS
 - (46) Ley; Synthesis 1975, V1975, P415
 - (47) Lotta, T; Journal of Computer-Aided Molecular Design 1992, V6, P253 HCAPLUS
 - (48) Lyall; J Bio Chem 1989, V264, P14503 HCAPLUS
 - (49) Marshall, E; Science 1993, V259, P618 MEDLINE
 - (50) Mitus; Textbook of Clinical Oncology P410
 - (51) Mosmann; J Immunol Methods 1983, V65, P55 MEDLINE
 - (52) Ohmichi; Biochemistry 1993, V32, P4650 HCAPLUS

- (53) Osborne; Cancer Research 1985, V45, P584 HCAPLUS
(54) Oshero; J Bio Chem 1993, V268, P11134 HCAPLUS
(55) Oshero; J Cell Biochem 1993, VS17A, P237
(56) Ozzello; Eur J Cancer 1980, V16, P553 MEDLINE
(57) O'Rourke; Clinical Oncology
(58) Pawson; Current Biology 1993, V3(7), P434 HCAPLUS
(59) Peterson; The Prostate 1993, V22, P335 HCAPLUS
(60) Pigott; Brit J of Neurosurgery 1993, V7, P261 MEDLINE
(61) Plowman; Nature 1993, V366, P473 HCAPLUS
(62) Pui; Textbook of Clinical Oncology P433
(63) Reddy; Cancer Research 1992, V52, P3636 HCAPLUS
(64) Rendu; Biochem Pharm 1992, V44(5), P881 HCAPLUS
(65) Rubens; Cancer Surveys 1993, V18, P199 MEDLINE
(66) Rusch; Cancer Research 1993, V53, P2379 HCAPLUS
(67) Rygaard; Acta path microbiol scand 1969, V77, P758 MEDLINE
(68) Samanta; Proc natl Acad Sci USA 1994, V91, P1711 HCAPLUS
(69) Sammes; J Chem Soc 1971, P2151 HCAPLUS
(70) Sarup; Growth Regulation 1991, V1, P72 MEDLINE
(71) Schlessinger; Neuron 1992, V9, P383 HCAPLUS
(72) Schlessinger, J; Trends Biochem Sci 1988, V13, P443 HCAPLUS
(73) Schornagel; Biochem Pharm 1984, V33(200), P3251
(74) Scott; J Bio Chem 1991, V266(22), P14300 HCAPLUS
(75) Seibert; Cancer Research 1983, V43, P2223 HCAPLUS
(76) Shafie; J Natl Cancer Institute 1981, V67(1), P51 HCAPLUS
(77) Shepard; Journal of Clinical Immunology 1991, V11, P117 HCAPLUS
(78) Skehan; J Natl Cancer Inst 1990, V82, P1107 HCAPLUS
(79) Slamon; Science 1987, V235, P177 HCAPLUS
(80) Sliwowski; J Biol Chem 1994, V269, P14661 HCAPLUS
(81) Spada; US 5302606 1994 HCAPLUS
(82) Stein; EMBO Journal 1994, V13(6), P1331 HCAPLUS
(83) Ullrich; Cell 1990, V61, P203 HCAPLUS
(84) Wada; Cell 1990, V61, P1339 HCAPLUS
(85) Wada; Oncogene 1990, V5, P489 HCAPLUS
(86) Warri; Int J Cancer 1991, V49, P616 HCAPLUS
(87) Yaish; Science 1988, V242, P933 HCAPLUS
(88) Yarden; Ann Rev Biochem 1988, V57, P443 HCAPLUS
(89) Yoneda; Cancer Research 1991, V51, P4430 HCAPLUS
(90) Zeillinger; Clin Biochem 1993, V26, P221 MEDLINE
IT 88404-44-8P 146871-70-7P 153436-53-4P
170449-14-6P 170449-15-7P 170449-16-8P
170449-17-9P 170449-18-0P 170449-19-1P
170449-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(receptor tyrosine kinase inhibitors, and prepn. thereof, for inhibiting cell proliferative disorders)


RN 88404-44-8 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 146871-70-7 HCAPLUS


CN 4-Quinazolinamine, N-(3-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153436-53-4 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 170449-14-6 HCAPLUS


CN 4-Quinazolinamine, N-(3-chlorophenyl)-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 170449-15-7 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 170449-16-8 HCAPLUS


CN 4-Quinazolinamine, N-(3-chlorophenyl)-6-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)




HCl

RN 170449-17-9 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 170449-18-0 HCAPLUS
 CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-, monohydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 170449-19-1 HCAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-methyl-, monohydrochloride
 (9CI) (CA INDEX NAME)



● HCl

RN 170449-20-4 HCAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




L92 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1998:401227 HCAPLUS
 DN 129:170172
 TI 4-(3'-Bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human **glioblastoma** cells
 AU Narla, Rama Krishna; Liu, Xing-Ping; Myers, Dorothea E.; Uckun, Fatih M.
 CS Department of Experimental Oncology, **Hughes** Institute, St. Paul, MN, 55113, USA
 SO Clinical Cancer Research (1998), 4(6), 1405-1414
 CODEN: CCREF4; ISSN: 1078-0432
 PB American Association for Cancer Research
 DT Journal
 LA English
 CC 1-6 (Pharmacology)
 AB The novel quinazoline deriv. 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154) exhibited significant cytotoxicity against U373 and U87 human **glioblastoma** cell lines, causing apoptotic cell death at micromolar concns. The in vitro **antiglioblastoma** activity of WHI-P154 was amplified >200-fold and rendered selective by conjugation to recombinant human epidermal growth factor (EGF). The EGF-P154 conjugate was able to bind to and enter target **glioblastoma** cells within 10-30 min via receptor (R)-mediated endocytosis by inducing internalization of the EGF-R mols. In vitro treatment with EGF-P154 resulted in killing of **glioblastoma** cells at nanomolar concns. with an IC50 of 813 +/- 139 nM, whereas no cytotoxicity against EGF-R-neg. leukemia cells was obsd., even at concns. as high as 100 .mu.M. The in vivo administration of EGF-P154 resulted in delayed tumor progression and improved tumor-free survival in a severe combined immunodeficient mouse **glioblastoma** xenograft model. Whereas none of the control mice remained alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and all control mice had tumors that rapidly progressed to reach an av. size of >500 mm3 by 58 days, 40% of mice treated for 10 consecutive days with 1 mg/kg/day EGF-P154 remained alive and free of detectable tumors for more than 58 days with a median tumor-free survival of 40 days. The tumors developing in the remaining 60% of the mice never reached a size >50 mm3. Thus, targeting WHI-P154 to the EGF-R may be useful in the treatment of **glioblastoma** multiforme.
 ST quinazoline deriv WHIP154 **glioblastoma** antitumor
 IT Drug targeting
 (**glioblastoma** inhibition by quinazoline deriv. WHI-P154 targeting of EGF receptor)
 IT Epidermal growth factor receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (**glioblastoma** inhibition by quinazoline deriv. WHI-P154 targeting of EGF receptor)
 IT **Neuroglia**
 (**glioblastoma**, inhibitors; **glioblastoma** inhibition)

- by quinazoline deriv. WHI-P154 targeting of EGF receptor)
- IT **Antitumor agents**
(**glioblastoma**; **glioblastoma** inhibition by
quinazoline deriv. WHI-P154 targeting of EGF receptor)
- IT 62229-50-9D, Epidermal growth factor, conjugates with quinazoline deriv.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL
(Biological study); RACT (Reactant or reagent); USES (Uses)
(**glioblastoma** inhibition by quinazoline deriv. WHI-P154
targeting of EGF receptor)
- IT 21561-09-1P 153436-54-5P 202475-60-3P 211555-04-3P
211555-05-4P 211555-06-5P 211555-07-6P
211555-08-7P 211555-09-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(**glioblastoma** inhibition by quinazoline deriv. WHI-P154
targeting of EGF receptor)
- IT 13790-39-1P, 4-Chloro-6,7-dimethoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(**glioblastoma** inhibition by quinazoline deriv. WHI-P154
targeting of EGF receptor)

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Anderson, P; Cancer Res 1995, V55, P1321 HCAPLUS
 - (2) Bos, M; Clin Cancer Res 1997, V3, P2099 HCAPLUS
 - (3) Brandes, A; Cancer Invest 1996, V14, P551 HCAPLUS
 - (4) Covey, T; Rapid Commun Mass Spectrom 1988, V2, P249 HCAPLUS
 - (5) Feng, R; J Am Soc Mass Spectrom 1991, V2, P387 HCAPLUS
 - (6) Finlay, J; Pediatric Neuro-Oncology 1992, P278
 - (7) Friedman, S; Cancer Res 1995, V55, P2853
 - (8) Fry, D; Science (Washington DC) 1994, V265, P1093 HCAPLUS
 - (9) Hoi, S; J Neurosurg 1995, V82, P841
 - (10) Khazaie, K; Cancer Metastasis Rev 1993, V12, P255 HCAPLUS
 - (11) Maruno, M; J Neurosurg 1991, V75, P97 MEDLINE
 - (12) Mendelsohn, J; Biologic Therapy of Cancer: Principles and Practice 1995,
P607
 - (13) Nomoto, F; Chem Pharm Bull 1990, V38, P1591
 - (14) Pardos, M; Cancer Medicine 1997, VI, P1471
 - (15) Pardos, M; Semin Surg Oncol 1998, V14, P88
 - (16) Thomas, C; Catalytic Processes and Proven Catalysts 1970, P1
 - (17) Torp, S; Cancer Immunol Immunother 1991, V33, P61 HCAPLUS
 - (18) Uckun, F; Clin Cancer Res 1998, V4, P1125 HCAPLUS
 - (19) Uckun, F; Clin Cancer Res 1998, V4, P901 HCAPLUS
 - (20) Uckun, F; J Clin Oncol 1997, V15, P2214 MEDLINE
 - (21) Uckun, F; Science (Washington DC) 1995, V267, P886 MEDLINE
 - (22) Waurzyniak, B; Clin Cancer Res 1997, V3, P881 HCAPLUS
 - (23) Yamazaki, H; Mol Cell Biol 1988, V8, P1816 HCAPLUS
- IT 21561-09-1P 153436-54-5P 211555-05-4P
211555-06-5P 211555-07-6P 211555-08-7P
211555-09-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(**glioblastoma** inhibition by quinazoline deriv. WHI-P154
targeting of EGF receptor)
- RN 21561-09-1 HCAPLUS
- CN 4-Quinazolinamine, 6,7-dimethoxy-N-phenyl- (9CI) (CA INDEX NAME)




RN 153436-54-5 HCAPLUS

CN 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 211555-05-4 HCAPLUS

CN Phenol, 2,6-dibromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-06-5 HCAPLUS

CN 4-Quinazolinamine, N-(3-bromo-4-methylphenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 211555-07-6 HCAPLUS

CN Phenol, 2-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 211555-08-7 HCAPLUS

CN Phenol, 3-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)





RN 211555-09-8 HCAPLUS

CN Phenol, 2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L92 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2003 ACS
 AN 1998:265828 HCAPLUS
 DN 128:294788
 TI 4-Aminoquinazoline derivatives for treatment of hyperproliferative disorders or conditions in mammals
 IN Arnold, Lee Daniel; Sobolov-Jaynes, Susan Beth
 PA Pfizer Inc., USA
 SO Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C07D403-12
 ICS A61K031-505; C07D239-88; C07D401-14; C07D401-06
 ICI C07D403-12, C07D239-00, C07D209-00
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 837063	A1	19980422	EP 1997-307724	19971001 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2218945	AA	19980417	CA 1997-2218945	19971015 <--
	JP 10152477	A2	19980609	JP 1997-284872	19971017 <--
	BR 9705088	A	19990720	BR 1997-5088	19971017 <--
PRAI	US 1996-28881P	P	19961017 <--		
OS	MARPAT 128:294788				
GI					



AB The title compds. I [R1 = CF3, halo, OH, etc.; Q1 = ArYX; Ar = monocyclic or bicyclic aryl or heteroaryl ring; X = C2 alkene, C2 alkyne or absent; Y = (CH2)p, wherein one or two of the CH2 groups may be replaced by either O, S, SO2, CO, NH or NMe; Z = NR3R4; R3 = H; R4 = Q2, Ph substituted by R5q, or NR3R4 = II, wherein the dotted line represents an optional double bond; m = 1, 2; n = 0, 1, 2, 3; o = 0, 1, 2; p = 0-5; q = 0-3 integer] and their pharmaceutically acceptable salts are prepd. Thus, heating (1H-indol-5-yl)-(6-iodo-7-methoxyquinazolin-4-yl)amine with

- 4-vinylpyridine, Pd acetate and NEt₃ in MeCN gave (1H-indol-5-yl)-[7-methoxy-6-(2-pyridin-4-yl-vinyl)quinazolin-4-yl]amine.
- ST hyperproliferative disorder aminoquinazoline deriv treatment; cancer aminoquinazoline deriv treatment; pyridinylvinyl quinazolinylamine prepn
- IT **Neoplasm**
(aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT Prostate gland
(benign hyperplasia; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(bladder carcinoma; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(**brain**; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT Bladder
(carcinoma, inhibitors; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT Esophagus
(disease, inhibitors; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(head; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT Skin, disease
(hyperplasia; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Brain, neoplasm**
Lung, neoplasm
Pancreas, neoplasm
Pancreas, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
Thyroid gland, neoplasm
(inhibitors; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(lung; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(mammary gland; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(neck; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT Head
Head
Mammary gland
Neck, anatomical
Neck, anatomical
(neoplasm, inhibitors; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
Antitumor agents
(pancreas; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
(stomach; aminoquinazoline derivs. for treatment of hyperproliferative diseases)
- IT **Antitumor agents**
Antitumor agents
(thyroid; aminoquinazoline derivs. for treatment of hyperproliferative diseases)

IT 206190-31-0P 206190-32-1P 206190-33-2P 206190-34-3P
206190-35-4P 206190-36-5P 206190-37-6P 206190-38-7P
 206190-39-8P 206190-40-1P 206190-41-2P 206190-42-3P 206190-43-4P
 206190-45-6P 206190-46-7P 206190-47-8P 206190-48-9P 206190-49-0P
 206190-50-3P 206190-51-4P 206190-52-5P 206190-55-8P 206190-57-0P
 206190-59-2P 206190-61-6P 206190-63-8P 206190-65-0P 206190-67-2P
 206190-70-7P 206190-72-9P 206190-74-1P 206190-76-3P 206190-79-6P
 206190-82-1P 206190-84-3P 206190-86-5P 206190-89-8P 206190-91-2P
 206190-95-6P 206190-96-7P 206190-99-0P 206191-02-8P 206191-03-9P
 206191-05-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aminoquinazoline derivs. for treatment of hyperproliferative diseases)

IT 98-80-6, Phenylboronic acid 100-43-6, 4-Vinylpyridine 109-04-6,
 2-Bromopyridine 536-74-3, Ethynylbenzene 555-57-7 1066-54-2,
 Trimethylsilyl acetylene 1945-84-2, 2-Ethynylpyridine 5192-03-0,
 5-Aminoindole 16064-08-7 50413-30-4 52537-00-5, 6-Chloroindoline
 54060-30-9, 3-Ethynylaniline 55777-84-9, Bromoaniline 131379-16-3
 157837-31-5 163105-90-6 183158-31-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(aminoquinazoline derivs. for treatment of hyperproliferative diseases)

IT **206190-21-8P** 206190-25-2P **206190-26-3P** 206190-27-4P
 206190-28-5P 206190-29-6P 206190-30-9P 206191-04-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(aminoquinazoline derivs. for treatment of hyperproliferative diseases)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Pfizer; WO 9523141 A HCAPLUS
- (2) Pfizer; WO 9630347 A HCAPLUS
- (3) Rhone-Poulenc Rorer International; WO 9220642 A HCAPLUS
- (4) Rhone-Poulenc Rorer Pharmaceuticals; WO 9515758 A HCAPLUS
- (5) The Wellcome Foundation; WO 9609294 A HCAPLUS
- (6) Zeneca; EP 0566226 A HCAPLUS
- (7) Zeneca; EP 0602851 A HCAPLUS
- (8) Zeneca; EP 0635498 A HCAPLUS
- (9) Zeneca; WO 9616960 A HCAPLUS


IT **206190-35-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aminoquinazoline derivs. for treatment of hyperproliferative diseases)

RN 206190-35-4 HCAPLUS

CN 4-Quinazolinamine, 6-ethynyl-N-1H-indol-5-yl-7-methoxy- (9CI) (CA INDEX NAME)




IT **206190-21-8P 206190-26-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(aminoquinazoline derivs. for treatment of hyperproliferative diseases)


RN 206190-21-8 HCAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-6-iodo- (9CI) (CA INDEX NAME)



RN 206190-26-3 HCAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-6-iodo-7-methoxy- (9CI) (CA INDEX NAME)



L92 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2003 ACS

AN 1996:530427 HCAPLUS

DN 125:185163

TI Tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors

AU Han, Yuchun; Caday, Cornelio Gacusana; Nanda, Anil; Cavenee, Webster K.; Huang, H-J.

CS Biomedical Res. Inst., Louisiana State Univ. Med. Cent., Shreveport, LA, 71130, USA

SO Cancer Research (1996), 56(17), 3859-3861

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

CC 1-6 (Pharmacology)

AB The effects of a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, tyrphostin AG 1478, were tested on three related human glioma cell lines: U87MG, which expressed endogenous wild-type (wt.) EGFR, and two retrovirally infected U87MG cell populations which overexpressed either wt. (U87MG.wtEGFR) or truncated EGFR (U87MG..DELTA.EGFR). Although AG 1478 inhibited cell growth, DNA synthesis, EGFR tyrosine kinase activity, and receptor autophosphorylation of each cell line tyrosine kinase activity, and receptor autophosphorylation of each cell line in a dose-dependent manner, it was significantly more potent in U87MG..DELTA.EGFR cells than in the other two cell lines. The increased inhibitory response of U87MG..DELTA.EGFR cells was due to a greater sensitivity of the constitutively autophosphorylated Mr 140,000 and 155,000 .DELTA.EGFR species to AG 1478. These results suggest that AG 1478 is a relatively specific inhibitor of the .DELTA.EGFR, and this finding may have important therapeutic implications since the .DELTA.EGFR occurs frequently in **glioblastomas** and in breast, lung, and

ovarian cancers.

ST tyrphostin AG 1478 glioma EGF receptor

IT **Neoplasm inhibitors**
 (tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)

IT **Receptors**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (epidermal growth factor/.alpha.-transforming growth factor, gene c-erbB, tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)

IT **Neuroglia**
 (neoplasm, tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)


IT **Animal growth regulator receptors**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.-transforming growth factor gene c-erbB, tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)

IT **153436-53-4, Tyrphostin AG 1478**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)

IT **153436-53-4, Tyrphostin AG 1478**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tyrphostin AG 1478 preferentially inhibits human glioma expressing truncated rather than wild-type epidermal growth factor receptors)

RN 153436-53-4 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L92 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:926425 HCAPLUS

DN 123:329984

TI Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders

IN Chen, Hui; Gazit, Aviv; Hirth, Klaus Peter; Levitzki, Alex; Mann, Elaina; Shawver, Laura K.; Tsai, Jianming; Tang, Peng Cho

PA Sugen, Inc., USA; Yisum Research Development Co.

SO PCT Int. Appl., 121 pp.
 CODEN: PIXXD2

DT Patent

LA English


IC ICM A61K031-275
 ICS A61K031-495; C07C327-44; C07C311-13; C07C317-14; C07C255-34;
 C07D241-52

CC 1-6 (Pharmacology)

Section cross-reference(s): 7, 25

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9524190	A2	19950914	WO 1995-US2826	19950306 <--
	WO 9524190	A3	19951109		
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9520968	A1	19950925	AU 1995-20968	19950306 <--
PRAI	US 1994-207933		19940307 <--		
	WO 1995-US2826		19950306 <--		
OS	MARPAT 123:329984				
GI					



I

- AB Receptor tyrosine kinase inhibitors I [R1-R3, R6 = alkyl, alkenyl, alkynyl, alkoxy, OH, amino, SH, alkylthio, halo, H, NO2, etc.; R4 = C(S)NHR5, C(O)NHR5, SO2YR5; Y = single bond, C(CN):CH:CH, azaalkyl; R5 = (substituted) aralkyl, CN] and II [R7-R10 = R1-R3 above; R12 = C(O)Me, C(S)Me, C(O)CF3, C(S)CF3; R13 = aryl, alkylaryl] are prep'd. for use in treating cell proliferative disorders such as cancers characterized by overactivity or inappropriate activity of HER2 receptors or EGF receptors. Thus, I [R1, R2 = OH, R3 = I, R4 = C(O)NH(CH2)3Ph, R6 = H] (III) was prep'd. in 2 steps by condensation of 5-iodovanillin with N-(3-phenylpropyl)cyanoacetamide. III inhibited EGF receptor kinase activity in EGC7 cells, HER2 kinase activity in BT-474 cells, and platelet-derived growth factor receptor kinase .beta. activity with an IC50 of 4, 18, and 35 .mu.M, resp., and inhibited growth of SKBR3 and SKOV3 cells in vitro at IC50 9 and 4.5 .mu.M, resp.
- ST receptor tyrosine kinase inhibitor prepn cancer; protein tyrosine kinase inhibitor cell proliferation
- IT **Neoplasm inhibitors**
Stomach, neoplasm
(receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)
- IT Ovary, neoplasm
Stomach, neoplasm
(adenocarcinoma, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)
- IT Animal growth regulator receptors
Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blood platelet-derived growth factor, overactivity of, neoplasm from; receptor tyrosine kinase inhibitors for inhibiting cell proliferative

disorders)

IT Uterus, neoplasm
(endometrium, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epidermal growth factor/.alpha.-transforming growth factor, gene c-erbB, receptor, protein tyrosine kinase of, inhibitors of; receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Intestine, neoplasm
(large, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Mammary gland
(neoplasm, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Salivary gland
(neoplasm, adenocarcinoma, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Mammary gland
(neoplasm, carcinoma, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT **Neuroglia**
(neoplasm, **glioblastoma**, receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p185c-erbB2, inhibitors; receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT Animal growth regulator receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.-transforming growth factor gene c-erbB, receptor, protein tyrosine kinase of, inhibitors of; receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 80449-02-1, Protein tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 101463-26-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein tyrosine kinase of, inhibitors of; receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 555-60-2P 5023-53-0P 5784-78-1P 6639-86-7P 10537-47-0P
13297-17-1P 13494-38-7P 15034-21-6P 23190-84-3P 40114-83-8P
54259-09-5P 57859-60-6P 65224-45-5P 65678-07-1P 70071-08-8P
71896-95-2P **88404-44-8P** 133550-41-1P 140674-76-6P
146871-70-7P 148741-30-4P 148741-31-5P 148741-32-6P
153436-53-4P 168835-81-2P 168835-82-3P 168835-83-4P
168835-87-8P 170448-88-1P 170448-89-2P 170448-90-5P 170448-91-6P
170448-92-7P 170448-94-9P 170448-95-0P 170448-96-1P 170448-97-2P
170448-98-3P 170448-99-4P 170449-00-0P 170449-01-1P 170449-02-2P
170449-03-3P 170449-04-4P 170449-05-5P 170449-06-6P 170449-07-7P
170449-08-8P 170449-09-9P 170449-10-2P 170449-11-3P 170449-12-4P
170449-13-5P **170449-14-6P 170449-15-7P**
170449-16-8P 170449-17-9P 170449-18-0P
170449-19-1P 170449-20-4P 170449-21-5P 170449-22-6P
170449-23-7P 170449-24-8P 170449-25-9P 170449-26-0P 170449-27-1P
170449-28-2P 170449-29-3P 170449-30-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 93-91-4, Benzoylacetone 94-02-0, Ethyl benzoylacetate 98-16-8,

3-Trifluoromethylaniline 99-40-1 100-46-9, Benzylamine, reactions
 103-79-7, Phenylacetone 105-34-0, Methyl cyanoacetate 108-42-9,
 3-Chloroaniline 109-76-2, 1,3-Propanediamine 109-77-3, Malononitrile
 109-80-8, 1,3-Propanedithiol 120-46-7, Dibenzoylmethane 123-54-6,
 Acetylacetone, reactions 139-85-5, 3,4-Dihydroxybenzaldehyde 480-96-6,
 Benzofuroxane 485-47-2, Ninhydrin 491-36-1, 4-Quinazolinone 579-07-7
 619-45-4, Methyl 4-aminobenzoate 704-13-2, 3-Hydroxy-4-nitrobenzaldehyde
 868-54-2, Malononitrile dimer 1074-12-0, Phenylglyoxal 1194-98-5,
 2,5-Dihydroxybenzaldehyde 1620-98-0 2038-57-5, 3-Phenylpropylamine
 2078-54-8, 2,6-Diisopropylphenol 2233-18-3, 3,5-Dimethyl-4-
 hydroxybenzaldehyde 2941-78-8, 5-Methyl-2-aminobenzoic acid 3171-45-7,
 4,5-Dimethyl-1,2-phenylenediamine 4389-45-1, 2-Amino-3-methylbenzoic
 acid 5348-42-5, 4,5-Dichloro-1,2-phenylenediamine 5438-36-8,
 5-Iodovanillin 7357-70-2 7605-28-9, Phenylsulfonylacetonitrile
 10412-93-8, N-Benzylcyanoacetamide 13790-39-1, 4-Chloro-6,7-
 dimethoxyquinazoline 14268-66-7, 3,4-Methylenedioxyaniline 16414-34-9
 24522-30-3 27869-04-1 37463-94-8, Sulfonyldiacetonitrile 40018-25-5
 54711-21-6 58421-79-7, 4-Chloro-6-methylquinazoline 105640-66-2
 133550-33-1 168835-79-8 170449-34-0 170449-35-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 1960-77-6P 5190-68-1P, 4-Chloroquinazoline 10537-86-7P 19181-53-4P
 19181-54-5P 27389-84-0P 29634-62-6P 58421-80-0P 111233-69-3P
 170449-31-7P 170449-32-8P 170449-33-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)

IT 62229-50-9, EGF 79079-06-4, EGF receptor protein tyrosine kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(receptor, protein tyrosine kinase of, inhibitors of; receptor tyrosine
 kinase inhibitors for inhibiting cell proliferative disorders)


IT 88404-44-8P 146871-70-7P 153436-53-4P
 170449-14-6P 170449-15-7P 170449-16-8P
 170449-17-9P 170449-18-0P 170449-19-1P
 170449-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders)


RN 88404-44-8 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 146871-70-7 HCAPLUS


CN 4-Quinazolinamine, N-(3-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153436-53-4 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 170449-14-6 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-8-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)


HCl

RN 170449-15-7 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)




RN 170449-16-8 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl


RN 170449-17-9 HCAPLUS

CN 4-Quinazolinamine, N-(3-chlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 170449-18-0 HCAPLUS


CN 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 170449-19-1 HCAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170449-20-4 HCAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-5-yl-6-methyl- (9CI) (CA INDEX NAME)



L92 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:861279 HCAPLUS

DN 124:21813

TI Treatment of platelet-derived growth factor related disorders such as cancers using inhibitors of platelet-derived growth receptor

IN Hirth, Klaus Peter; Schwartz, Donna Pruess; Mann, Elaina; Shawver, Laura Kay; Keri, Gyorgy; Szekely, Istvan; Bajor, Tamas; Haimichael, Janis; Orfi, Laszlo; et al.

PA Sugen, Inc., USA; Biosignal Ltd.; Yisum Research Development Co.; Max-Planck-Gesellschaft zur Forderung der Wissenschaften v.V.; Regents of

the University of California
 SO PCT Int. Appl., 154 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-42
 ICS A61K031-275; A61K031-415; A61K031-40; A61K031-535; C07C251-86;
 A61K031-505; A61K031-47; A61K031-495; A61K031-44; A61K031-165;
 C07D231-38; C07D239-88; C07D241-42; C07D487-04; C07C255-23;
 C07C255-41
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 2, 28, 63

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519169	A2	19950720	WO 1995-US363	19950106 <--
WO 9519169	A3	19960215		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
RW: KE, MW, SD, SZ; AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5700823	A	19971223	US 1994-179570	19940107 <--
CA 2180658	AA	19950720	CA 1995-2180658	19950106 <--
AU 9515633	A1	19950801	AU 1995-15633	19950106 <--
AU 690958	B2	19980507		
CN 1128496	A	19960807	CN 1995-190013	19950106 <--
CN 1065744	B	20010516		
EP 804191	A1	19971105	EP 1995-907382	19950106 <--
EP 804191	B1	20000517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1000617	A2	20000517	EP 1999-118607	19950106 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 192925	E	20000615	AT 1995-907382	19950106 <--
ES 2149966	T3	20001116	ES 1995-907382	19950106 <--
MX 9602680	A	20000630	MX 1996-2680	19960708 <--
AU 9878832	A1	19981008	AU 1998-78832	19980806 <--
AU 718272	B2	20000413		
PRAI US 1994-179570	A	19940107	<--	
EP 1995-907382	A3	19950106	<--	
WO 1995-US363	W	19950106	<--	

OS MARPAT 124:21813

AB Compds. are disclosed which can inhibit platelet-derived growth factor receptor (PDGF-R) activity; preferably, such compds. also inhibit the activity of other members of the PDGF-R superfamily and are selective for members of the PDGF-R superfamily. The PDGF-R superfamily includes PDGF-R and PDGF-R-related kinases Flt and KDR. The featured compds. are active on cell cultures to reduce the activity of the PDGF-R and preferably .gtoreq.1 PDGF-R-related kinases. Using the present application as guide, other compds. able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compds. are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity. Compd. A10 (leflunomide) inhibited PDGF-R autophosphorylation, PDGF-stimulated DNA synthesis, cell cycle progression, and a variety of tumor types. Prepn. and biol. testing of a large no. of other compds. is included.

ST PDGF receptor inhibitor prepn therapeutic; antitumor PDGF receptor inhibitor prepn; leflunomide PDGF receptor inhibition cancer treatment

IT Immunoglobulins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

- (leflunomide effect on immune response in relation to platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Brain**
 Cell cycle
 Cell proliferation
 Deoxyribonucleic acid formation
 Fibrosis
Neoplasm inhibitors
 Phosphorylation, biological
 (platelet-derived growth factor inhibitors and their prepn. for treatment of **cancer** and other PDGF-related disorders)
- IT **Cytotoxic agents**
 (platelet-derived growth factor inhibitors, their prepn. for treatment of cancer and other PDGF-related disorders, and their use with cytotoxic agents)
- IT **Neoplasm inhibitors**
 (Kaposi's sarcoma, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Lymphocyte**
 (T-cell, cytotoxic, leflunomide effect on immune response in relation to platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Antiarteriosclerotics**
 (antiatherosclerotics, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Animal growth regulator receptors**
 Receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (blood platelet-derived growth factor, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Animal growth regulators**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (blood platelet-derived growth factors, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
 (**brain**, platelet-derived growth factor inhibitors and their prepn. for treatment of **cancer** and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
 (colon, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Intestine, neoplasm**
 (colon, inhibitors, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Receptors**
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (epidermal growth factor/.alpha.-transforming growth factor, gene c-erbB, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
 (epidermoid, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Liver, disease**
 (fibrosis, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
 (glioma, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

- IT **Brain, neoplasm**
Lung, neoplasm
Ovary, neoplasm
(inhibitors, platelet-derived growth factor inhibitors and their prepn. for treatment of **cancer** and other PDGF-related disorders)
- IT Lymphokines and Cytokines
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(interleukin 6, leflunomide effect on immune response in relation to platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(leukemia, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(lung, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(mammary gland, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(melanoma, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Kidney, disease
(mesangial proliferative glomerulonephritis, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Mammary gland
Neuroglia
Prostate gland
(neoplasm, inhibitors, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(ovary, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p185c-erbB2, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Blood vessel, disease
(proliferative, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT **Neoplasm inhibitors**
(prostate gland, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vascular endothelial growth factor, gene KDR, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vascular endothelial growth factor, gene flk-1, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vascular endothelial growth factor, gene flt-1, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT Animal growth regulator receptors

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.-transforming growth factor gene c-erbB, platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 50-99-7, Dextrose, biological studies 67-68-5, DMSO, biological studies 100-51-6, Benzenemethanol, biological studies 9005-65-6, Polysorbate 80 25322-68-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(leflunomide efficacy with respect to formulation)
- IT 75706-12-6P, Leflunomide
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 146535-11-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 5021-43-2P 6940-85-8P 14548-00-6P 15950-40-0P **21561-09-1P**
40353-41-1P 57433-51-9P 62004-16-4P, 2-Butenamide, 2-cyano-3-hydroxy-N-(4-nitrophenyl)- 71897-07-9P 78751-23-2P 103977-08-8P 124844-98-0P 133900-14-8P 136186-01-1P 143993-60-6P 158081-91-5P 158081-92-6P, 1H-Pyrazole-3-acetonitrile, 5-amino-4-cyano-.alpha.-[[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methylene]- 158102-45-5P 158102-46-6P 160953-96-8P 167018-37-3P 167018-39-5P 167427-78-3P 168835-90-3P 168835-98-1P 169120-19-8P 169120-20-1P 169120-22-3P 169120-23-4P 169120-25-6P 169120-26-7P 169120-27-8P 169120-28-9P 169120-29-0P 169120-30-3P 169120-31-4P 169120-32-5P 169120-33-6P 169120-34-7P 169120-35-8P 169120-36-9P 169120-37-0P 169120-38-1P 169120-39-2P 169120-40-5P 169120-41-6P 169120-42-7P 169120-43-8P 169120-44-9P 169120-45-0P 169120-46-1P 169120-47-2P 169120-48-3P 169120-49-4P 169120-50-7P 169120-57-4P 169120-58-5P 169120-71-2P 169120-72-3P 171828-64-1P 172868-04-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 168835-89-0 169120-52-9 169120-54-1 169120-55-2 169120-56-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 80449-02-1, Tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)
- IT 169120-18-7P
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 75-36-5, Acetyl chloride 89-98-5, 2-Chlorobenzaldehyde 90-02-8, 2-Hydroxybenzaldehyde, reactions 90-04-0, 2-Methoxyaniline 91-16-7, Veratrole 94-02-0 94-70-2, 2-Ethoxyaniline 95-54-5, o-Phenylene diamine, reactions 95-92-1, Diethyl oxalate 99-09-2, 3-Nitroaniline 99-40-1 99-56-9 99-98-9, (4-Dimethylamino)aniline 100-01-6, 4-Nitroaniline, reactions 100-19-6 100-46-9, Benzylamine, reactions 100-83-4, 3-Hydroxybenzaldehyde 103-80-0, Phenylacetyl chloride 105-56-6, Cyanoacetic acid ethyl ester 107-91-5, 2-Carboxamidoacetonitrile 107-95-9, .beta.-Alanine 108-12-3, Isovaleryl chloride 108-24-7, Acetic anhydride 118-92-3, Anthranilic acid 123-08-0, 4-Hydroxybenzaldehyde 139-85-5, 3,4-Dihydroxybenzaldehyde 298-12-4 328-74-5, 3,5-Bis(trifluoromethyl)aniline 352-11-4, 4-Fluorobenzyl chloride 372-09-8, Cyanoacetic acid 452-58-4, 2,3-Diaminopyridine 455-14-1, 4-Trifluoromethylaniline 487-89-8, 3-Formylindole 496-15-1, Indoline 496-72-0, 3,4-Diaminotoluene 527-72-0, Thiophene-2-carboxylic acid 540-37-4, p-Iodoaniline 591-27-5, 3-Hydroxyaniline 611-73-4, Benzoyl formic acid 626-01-7, m-Iodoaniline 771-97-1, 2,3-Diaminonaphthalene 868-54-2, Malononitrile dimer 1075-06-5, Phenyl glyoxal hydrate 1125-80-0, 3-Methylisoquinoline 1196-69-6, 5-Formylindole 1620-98-0 1871-76-7, Diphenylacetyl chloride 2251-50-5, Pentafluorobenzoyl chloride 3171-45-7, 4,5-Dimethyl-1,2-phenylenediamine 3586-15-0, 3-Phenoxybenzoyl chloride 4974-57-6, 4-Nitrophenyl glyoxal 5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5653-40-7, 4,5-Dimethoxy-2-aminobenzoic acid 7357-70-2 13677-79-7, 3,4,5-Trihydroxybenzaldehyde 16414-34-9 19650-95-4 23860-35-7, Cyclohexylacetyl chloride 31301-45-8, 3,5-Dimethylisoxazole-4-carbonyl chloride 37463-94-8, Sulfonyl diacetonitrile 39070-63-8 41927-01-9, 3,4-Dimethyl-1,2-phenylenediamine 105640-66-2 111233-69-3 133550-31-9 133550-33-1 133550-57-9 168836-05-3 169120-63-2 169120-64-3 169120-65-4 169120-66-5 169120-67-6 169120-68-7 169120-69-8 169120-70-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 351-87-1P 785-74-0P 3395-03-7P, 1,2-Dinitro-4,5-dimethoxybenzene 7267-26-7P 7501-69-1P 10376-59-7P 13790-39-1P, 4-Chloro-6,7-dimethoxyquinazoline 13794-72-4P 21774-44-7P 22208-39-5P 24439-50-7P 24451-13-6P 24522-30-3P 28082-82-8P, 6,7-Dimethylquinoxaline-2-one 29067-81-0P, 2-Chloro-6,7-dimethylquinoxaline 40821-48-5P 53117-23-0P 53117-28-5P 54711-21-6P 61643-55-8P 67394-73-4P 75706-11-5P 105780-30-1P, 2-Methoxy-4,5-dinitrophenol 127916-11-4P 169120-60-9P 169120-61-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 169120-62-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 61643-23-0P 143993-59-3P, Imidazo[5,1-b]quinazolin-9(1H)-one, 2,3-dihydro-1-(2-hydroxyphenyl)-3-methyl-2-(phenylmethyl)- 143993-61-7P 169120-73-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 134888-93-0 169120-51-8 169120-53-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)


IT 15663-27-1, Cisplatin 33419-42-0, VP-16
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(platelet-derived growth factor inhibitors, their prepn. for treatment of cancer and other PDGF-related disorders, and their use with cytotoxic agents)

IT 62229-50-9, EGF
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (receptor; platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

IT 21561-09-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (platelet-derived growth factor inhibitors and their prepn. for treatment of cancer and other PDGF-related disorders)

RN 21561-09-1 HCAPLUS
 CN 4-Quinazolinamine, 6,7-dimethoxy-N-phenyl- (9CI) (CA INDEX NAME)



=> fil hcaold
 FILE 'HCAOLD' ENTERED AT 17:39:06 ON 11 JUN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
 FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d l63 all tot

L63 ANSWER 1 OF 20 HCAOLD COPYRIGHT 2003 ACS
 AN CA64:11208d CAOLD
 TI antibacterials - (VII)
 AU Goud, A. Nagana; Jamkhandi, P. S.; Rajagopal, S.
 IT 3458-43-3 3458-44-4 3458-45-5
 3458-46-6 3458-47-7 3458-48-8
 3458-49-9 3458-50-2 3545-15-1 5271-13-6
 5271-14-7 5271-15-8 5271-16-9 5375-97-3

L63 ANSWER 2 OF 20 HCAOLD COPYRIGHT 2003 ACS
 AN CA59:627h CAOLD
 TI reaction of 4-quinazolinecarbonitrile with nucleophilic reagents - (II) with Grignard reagents, (III) with ketones, (IV) with active methylene

comps.

AU Higashino, Takeo
IT 491-36-1 603-23-6 700-46-9 963-80-4 1087-99-6 1221-88-1
1701-95-7 2400-93-3 2400-95-5 2400-97-7 2473-93-0 2603-56-7
4127-49-5 13905-52-7 16332-86-8 17629-01-5 22522-59-4 22522-60-7
25326-52-7 25330-81-8 36082-71-0 36925-12-9 36926-85-9 80602-16-0
91391-93-4 91806-26-7 91902-13-5 91954-88-0 92057-17-5
92437-11-1 92872-63-4 93333-17-6 94878-99-6

L63 ANSWER 3 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:9267h CAOLD

TI residual oily soil as a factor in yellowing of used and laundered white cotton articles

AU McLendon, Verda; Richardson, F.

IT 5395-37-9 17329-27-0 17329-31-6 27440-42-2 34932-33-7
51829-62-0 59674-85-0 90004-09-4 92193-49-2
93016-25-2 93533-57-4 93734-34-0
93734-39-5 94539-18-1 94539-19-2 105164-82-7

L63 ANSWER 4 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:9267a CAOLD

TI photographic layers for the Ag bleach process

PA CIBA Ltd.

DT Patent

PATENT NO.	KIND	DATE
------------	------	------

PI BE 611898
CH 404398
DE 1138318
GB 940286
US 3211555

1965

IT 69220-17-3 74094-65-8 93871-19-3 94068-90-3
94255-57-9 94544-57-7 95157-12-3 96170-29-5 96763-40-5
103070-46-8 103102-35-8 105793-24-6 107279-31-2

L63 ANSWER 5 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:5682c CAOLD

TI 3-p-toluenesulfonyl-4-quinazolinone and some of its reactions

AU Bunnett, Joseph F.; Bassett, J. Y.

IT 5465-78-1 6344-76-9 16347-60-7 92191-95-2 92966-52-4
92966-53-5

L63 ANSWER 6 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:4564c CAOLD

TI aryl .beta.-amino acids - (II) .beta.-phenyl-.beta.-ureido acids and related compds., (III) action of POCl₃ on 6-aryl-5,6-dihydrouracils

AU Chernova, N. G.; Berlin, A. Ya.

IT 733-70-0 6300-95-4 90840-43-0 90872-08-5 90946-83-1 91646-91-2
91687-58-0 91961-23-8 91961-24-9 91961-30-7
92026-80-7 92104-32-0 92104-33-1 92104-44-4
92796-81-1 92796-82-2 92866-48-3 92866-49-4 93042-57-0 93256-37-2
93283-90-0 93439-93-1 93569-10-9 93864-49-4

L63 ANSWER 7 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:4563h CAOLD

TI substituted phenyl quinazolyl sulfides and sulfones - (I), (II)
4-hydroxychlorophenyl 4-quinazolyl sulfides and sulfones

AU Badiger, Virupax V.; Nargund, K. S.

IT 23945-54-2 91961-28-3 91961-29-4 92104-39-7
92104-51-3 92188-63-1 92188-64-2
92188-65-3 92188-66-4 93256-36-1 93354-15-5
93354-26-8

L63 ANSWER 8 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:4563e CAOLD

TI substituted phenyl quinazolyl ethers

AU Badiger, Virupax V.; Nargund, K. S.

IT 83529-86-6 91961-12-5 91961-18-1
 91961-19-2 91961-20-5 92060-62-3
 92104-24-0 92104-25-1 92167-51-6
 92437-27-9 92437-28-0 92868-56-9 92905-84-5
 93256-33-8 93354-13-3 93866-11-6
 93866-12-7 93866-13-8 94064-23-0 94205-75-1
 94753-50-1 94802-96-7 96417-92-4
 96433-79-3 96652-95-8 96652-96-9

L63 ANSWER 9 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:1475c CAOLD

TI piperazines

AU Morren, Henri

DT Patent

PATENT NO.	KIND	DATE
-----	-----	----

PI BE 614177

DE 1178435

FR M1932

GB 938646

US 3163649 1964

IT 16064-11-2 16064-13-4 16064-14-5 16064-23-6 16347-95-8 16347-96-9
 16347-97-0 17329-31-6 19181-54-5 19181-64-7 20386-24-7
 92493-50-0 92493-51-1 92493-68-0 93808-18-5 93808-19-6 93808-34-5
 97213-43-9

L63 ANSWER 10 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA58:521d CAOLD

TI polyazanaphthalenes - (VII) derivs. of quinazoline and
 1,3,5-triazanaphthalene

AU Oakes, Vincent; Rydon, H. N.; Undheim, K.

IT 1955-60-8 1955-61-9 1955-62-0 1955-63-1 2312-90-5 19181-53-4
 21419-47-6 39576-82-4 50440-82-9 51989-24-3 58421-79-7 62484-16-6
 87610-96-6 90537-56-7 91647-26-6 92043-92-0 92327-92-9
 92554-57-9 92659-18-2 92872-02-1 93020-69-0 93734-33-9
 94066-18-9 94207-37-1 94872-21-6 95225-61-9 96581-92-9 97191-89-4
 100150-39-8 100266-92-0 100768-45-4

L63 ANSWER 11 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA57:7269g CAOLD

TI reaction of anthranilonitrile and N-methyl-anthranilonitrile with phenyl
 isocyanate and phenyl isothiocyanate

AU Taylor, Edward C.; Ravindranathan, R. V.

IT 491-36-1 607-19-2 1885-29-6 4248-15-1 13114-96-0 13906-09-7
 14505-32-9 17583-40-3 18741-24-7 21097-36-9 34923-95-0
 35565-62-9 35696-83-4 53412-77-4 67461-76-1
 67461-77-2 73987-32-3 92165-07-6 92554-63-7 92554-69-3
 92554-70-6 92555-54-9 92969-09-0

L63 ANSWER 12 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA55:5516c CAOLD

TI 2-deoxy-D-ribose - (IV) direct synthesis of 2'-deoxyadenosine and its
 anomer through 2-deoxy-D-ribose derivs.

AU Ness, Robert K.; Fletcher, H. G., Jr.

IT 958-09-8 3413-66-9 6324-83-0 34923-95-0 99828-33-8
 102048-79-3 108747-25-7 108942-64-9 112484-75-0 113134-87-5 121124-08-1

L63 ANSWER 13 OF 20 HCAOLD COPYRIGHT 2003 ACS

AN CA55:5515i CAOLD
TI reaction of 4-quinazolinecarbonitrile with nucleophilic reagents - (I)
AU Higashino, Takeo
IT 491-36-1 16347-95-8 16347-96-9 **16347-97-0** 22754-07-0
36075-44-2 36082-71-0 41229-10-1 41270-82-0 60262-41-1

L63 ANSWER 14 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA54:14706c CAOLD
TI dyes (anthraquinone vat)
PA Badische Anilin- & Soda-Fabrik Akt.-Ges.
DT Patent
TI vat-dye filter cakes, conditioning of
PA Allied Chemical Corp.
DT Patent

PATENT NO.	KIND	DATE
GB 829699		
DE 1073130		
DE 1073132		
US 2930792		1960
102442-56-8	104510-69-2	106168-09-6 108247-01-4 108247-02-5
	108722-09-4	108988-84-7 109534-95-4 114327-73-0

L63 ANSWER 15 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:15527e CAOLD
TI prepn. of quinazoline derivs. through ringclosure of aromatic o-cyano acylamino compds. in alk. alc. or phenolic medium - (I) 4-RO-substituted quinazolines
AU Breukink, K. W.; Krol, L. H.; Verkade, P. E.; Wepster, B. M.
IT 491-36-1 635-21-2 1022-45-3 1885-29-6 5190-68-1 5922-60-1
16347-95-8 22302-63-2 25116-00-1 26060-03-7 **34297-92-2**
36253-00-6 40288-69-5 53312-90-6 53902-59-3 63069-48-7 91350-36-6
96461-53-9 98947-27-4 99853-58-4 101423-45-4 101443-82-7 101871-79-8
102467-33-4 107519-02-8 110249-21-3 110249-22-4 130862-63-4

L63 ANSWER 16 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:12988e CAOLD
TI N-alkyl-2-amino-4-hydroxy-5-pyrimidine-carboxamides (basically substituted) and salts thereof
PA Searle, G. D., & Co.
DT Patent
TI basically substituted N-alkyl-2-amino-4-hydroxy-5-pyrimidinecarboxyamides and salts thereof
AU Rorig, Kurt J.; Nichol森, R. T.
DT Patent
TI quinazoline derivs.
AU Spinks, Alfred; Young, E. H. P.
PA Imperial Chemical Industries Ltd.
DT Patent

PATENT NO.	KIND	DATE
US 2789979		1957
US 2794018		1957
19815-15-7	79689-29-5	98436-60-3 98556-36-6 98556-99-1 99069-45-1
	99069-46-2	99178-94-6 99584-26-6 99584-27-7 100061-70-9 100120-59-0
100541-03-5	100970-63-6	101872-19-9 101872-20-2 102879-85-6
	104037-04-9	104741-28-8 108106-00-9 117147-24-7

L63 ANSWER 17 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:9625b CAOLD
TI potential amebicides - (III) synthesis of 4-substituted amino-8-hydroxy(and 8-methoxy) quinazolines and 3-substituted 8-hydroxy(and 8-methoxy)-4-quinazolones

AU Iyer, R. N.; Anand, N.; Dhar, M. L.
IT 16064-17-8 16064-27-0 90417-39-3 90915-44-9 90915-46-1 91351-03-0
91351-04-1 91567-04-3 91567-06-5 91820-23-4 92108-42-4 92327-15-6
92327-16-7 92437-62-2 92703-59-8 95126-63-9 100060-90-0 100373-89-5
100705-56-4 100705-57-5 100705-58-6 100719-79-7 **100865-50-7**
100951-83-5 101012-61-7 **101094-90-0** 101284-88-2 101350-82-7
101436-97-9 101494-80-8 101740-34-5 101867-72-5 102371-40-4 102875-01-4
103039-18-5 104296-29-9 104510-25-0 104742-93-0 106739-73-5 106883-65-2
107154-28-9 **108717-76-6** 108717-98-2 110147-73-4 110147-74-5
112441-16-4 113796-28-4 131869-04-0

L63 ANSWER 18 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:6646a CAOLD
TI synthesis of 2,4-diaryloaminoquinazoline and its derivs. - (II)
AU Dymek, Wojciech; Malicki, J.; Waksmundzka, A.
IT 4603-59-2 17284-97-8 19064-67-6 40954-04-9 58826-43-0 59019-09-9
67449-23-4 98334-49-7 98489-60-2 99419-04-2 99984-42-6 102442-17-1
103505-53-9 **108719-42-2** 113510-84-2 115209-85-3 116212-93-2

L63 ANSWER 19 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:5095d CAOLD
TI reactions of acetamide with aniline and phenylisothiocyanate
AU Dymek, Wojciech; Brzozowska, N.; Brzozowski, T.
IT 27142-44-5 **67461-77-2** **101101-77-3** 102477-60-1
102754-69-8 110060-39-4 **111936-87-9** 114331-20-3 115145-19-2
115209-55-7

L63 ANSWER 20 OF 20 HCAOLD COPYRIGHT 2003 ACS
AN CA51:1303g CAOLD
TI 2-(.gamma.-diethylaminopropoxy)-4,6-dimethylpyrimidine and its salts
AU Burtner, Robert R.
PA Searle, G. D., & Co.
DT Patent
PATENT NO. KIND DATE

PI US 2748123 1956
IT 98556-99-1 **100541-03-5** 106037-87-0 106037-88-1 117147-24-7

=> d his

(FILE 'HOME' ENTERED AT 16:39:15 ON 11 JUN 2003)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 16:39:56 ON 11 JUN 2003

E UCKUN F/AU
L1 432 S E4-E9
L2 5 S L1 AND (CJUN OR C JUN)
L3 28 S L1 AND (JAK3 OR JAK 3)
L4 17 S L1 AND (JANUS KINASE OR JANUSKINASE)()3
L5 2 S L2 AND L3,L4
L6 1 S L5 AND P/DT
SEL RN

FILE 'REGISTRY' ENTERED AT 16:41:54 ON 11 JUN 2003

L7 6 S E1-E6
L8 2 S L7 AND 3/NR
SEL RN
L9 20 S E7-E8/CRN

FILE 'HCAOLD' ENTERED AT 16:43:49 ON 11 JUN 2003

L10 0 S L8 OR L9

FILE 'USPATFULL, USPAT2' ENTERED AT 16:43:53 ON 11 JUN 2003

L11 33 S L8 OR L9
E UCKUN F/AU

L12 31 S E4-E8 AND L11
E WAYNE/PA

L13 0 S E21 AND L11
E PARKER/PA,CS

L14 25 S E109,E110 AND L11

L15 33 S L11,L12,L14

L16 1 S L15 AND (PD<=19980630 OR PRD<=19980630 OR AD<=19980630)

L17 32 S L15 NOT L16

FILE 'REGISTRY' ENTERED AT 16:47:37 ON 11 JUN 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 16:48:05 ON 11 JUN 2003

FILE 'REGISTRY' ENTERED AT 16:51:41 ON 11 JUN 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 16:52:31 ON 11 JUN 2003

L18 31 S L17 NOT COMPUTER/TI

L19 15 S L18 AND (CJUN OR C JUN OR JAK 3 OR (JANUSKINASE OR JANUS KINA

FILE 'REGISTRY' ENTERED AT 16:55:51 ON 11 JUN 2003

E JANUS KINASE/CN

L20 1 S E7

FILE 'USPATFULL, USPAT2' ENTERED AT 16:57:52 ON 11 JUN 2003

L21 38 S L20

L22 49 S (JAK3 OR JAK 3) () (KINASE OR PROTEIN KINASE OR TYROSINE KINASE

L23 107 S JAK KINASE

L24 152 S L21-L23

L25 14 S L18 AND L24

L26 15 S L19,L25

L27 15 S L26 AND L17

L28 0 S L27 AND (CJUN OR C JUN)

L29 32 S L17,L25-L27

FILE 'REGISTRY' ENTERED AT 16:59:48 ON 11 JUN 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 17:00:41 ON 11 JUN 2003

FILE 'HCAPLUS' ENTERED AT 17:01:09 ON 11 JUN 2003

L30 37 S L8 OR L9

L31 33 S WHI() (P131 OR P154 OR P() (131 OR 154)) OR WHIP131 OR WHIP154

L32 44 S L30,L31

L33 8 S L32 AND (PD<=19980630 OR PRD<=19980630 OR AD<=19980630)

L34 6 S L33 AND L1

L35 6 S L33 AND (HUGHES OR WAYNE OR PARKER)/PA,CS

L36 8 S L33-L35

L37 2 S L36 AND (CJUN OR C JUN)

L38 2 S L36 AND L24

L39 1 S L36 AND (JANUSKINASE OR JANUS KINASE OR JAK3)

L40 8 S L36-L39

FILE 'HCAPLUS' ENTERED AT 17:04:59 ON 11 JUN 2003

FILE 'EMBASE' ENTERED AT 17:06:08 ON 11 JUN 2003

L41 25 S L32

L42 2 S L41 AND PY<=1998
E "4 3' BROMO 4' HYDROXYLPHENYL AMINO 6 7 DIMETHOXYQUINAZOLINE"
E "4 3 BROMO 4 HYDROXYLPHENYL AMINO 6 7 DIMETHOXYQUINAZOLINE"/C
E "4 (3' BROMO 4' HYDROXYLPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE

L43 4 S E3-E16

E "4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE"/CT
L44 6 S E3-E10
L45 0 S L43,L44 NOT L41
L46 2 S L42 AND L43,L44

FILE 'MEDLINE' ENTERED AT 17:09:49 ON 11 JUN 2003
L47 24 S L32
L48 8 S 4 3 BROMO 4 HYDROXYLPHENYL AMINO 6 7 DIMETHOXYQUINAZOLINE OR
L49 2 S L47,L48 AND PY<=1998

FILE 'EMBASE, MEDLINE' ENTERED AT 17:11:34 ON 11 JUN 2003
L50 2 DUP REM L46 L49 (2 DUPLICATES REMOVED)

FILE 'EMBASE, MEDLINE' ENTERED AT 17:11:44 ON 11 JUN 2003

FILE 'BIOSIS' ENTERED AT 17:11:52 ON 11 JUN 2003
L51 29 S L32 OR L48
L52 2 S L51 AND PY<=1998

FILE 'BIOSIS' ENTERED AT 17:12:54 ON 11 JUN 2003

FILE 'REGISTRY' ENTERED AT 17:13:13 ON 11 JUN 2003
L53 STR
L54 41 S L53 CSS SAM
L55 3070 S L53 CSS FUL
SAV L55 HOPE345/A
L56 STR L53
L57 50 S L56 CSS SAM SUB=L55
L58 1124 S L56 CSS FUL SUB=L55
SAV L58 HOPE345A/A
L59 STR L56
L60 7 S L59 CSS SAM SUB=L55
L61 135 S L59 CSS FUL SUB=L55
SAV L61 HOPE345B/A
L62 1237 S L58,L61 NOT L8,L9

FILE 'HCAOLD' ENTERED AT 17:26:19 ON 11 JUN 2003
L63 20 S L62

FILE 'REGISTRY' ENTERED AT 17:27:06 ON 11 JUN 2003
L64 73 S L62 AND CAOLD/LC

FILE 'HCAPLUS' ENTERED AT 17:27:33 ON 11 JUN 2003
L65 389 S L62
L66 18 S L65 AND L1
L67 18 S L65 AND (HUGHES? OR PARKER? OR WAYNE?)/PA,CS
L68 18 S L66,L67
L69 9 S L65 AND L24
L70 6 S L65 AND (JANUSKINASE OR JANUS KINASE)
L71 5 S L65 AND (CJUN OR C JUN)
L72 218 S L65 AND (PD<=19980630 OR PRD<=19980630 OR AD<=19980630)
L73 2 S L72 AND L68
L74 1 S L72 AND L69-L71
L75 3 S L73,L74
L76 207 S L65 AND PY<=1998
L77 0 S L76 AND L69-L71
L78 218 S L72,L76
E GLIOBLASTOMA/CT
E E3+ALL
L79 2709 S E2
L80 579 S E6
L81 4355 S ?GLIOBLASTOM?
E NEUROGLIA/CT

L82 31326 E E3+ALL
 S E5+NT
 E BRAIN NEOPLASM/CT
 E E4+ALL
 E E2+ALL
L83 4860 S E7,E6+NT
L84 9 S L78 AND L79-L83
L85 3 S L78 AND BRAIN(L) (?CANCER? OR ?TUMOR? OR ?NEOPLAS? OR ?MALIGN
L86 10 S L84,L85,L75
 E ANTITUMOR/CT
 E E5+ALL
L87 158675 S E4,E3,E20-E26
L88 30685 S E28+NT OR E29+NT OR E30+NT
L89 214899 S E31+NT
L90 73 S L78 AND L87-L89
L91 9 S L90 AND L86
L92 10 S L86,L91

FILE 'REGISTRY' ENTERED AT 17:38:18 ON 11 JUN 2003

FILE 'HCAPLUS' ENTERED AT 17:38:38 ON 11 JUN 2003

FILE 'HCAOLD' ENTERED AT 17:39:06 ON 11 JUN 2003